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 Abstract 
 
The multiple pterygium syndromes are a heterogeneous group of conditions in which 
arthrogryposis (joint contractures), pterygia (webbing) and a variety of other developmental 
anomalies are present. It is caused by lack of fetal movement in the womb. Mutations in 
CHRNG, the embryonic subunit of the acetylcholine receptor (AChR), cause some of the 
cases. CHRNG mutation analysis was undertaken in a large patient cohort of 100 families and 
the mutations identified were included in a new Locus Specific Database. Genotype 
phenotype analysis showed that pterygia were almost invariably present in the CHRNG 
mutation positive patients. 
 
It was hypothesised that mutations in other genes necessary for fetal AChR function may 
cause fetal akinesia. Using a candidate gene approach a homozygous frameshift mutation in 
RAPSN was identified in one family and a homozygous splice site DOK7 mutation in second 
family. Mild mutations in both RAPSN and DOK7 have been previously identified in the 
congenital myasthenic syndromes (CMS). Thus, mild mutations in RAPSN and DOK7 cause 
CMS whereas severe mutations cause fetal akinesia. 
 
Finally, work was done to identify a novel cause of fetal akinesia in a consanguineous family 
using an autozygosity mapping approach. A region of homozygosity was located and 
candidate genes sequenced.  
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Chapter 1: General Introduction
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1.1 Introduction  
 
This project was designed to study the multiple pterygium spectrum disorders, a group of rare 
conditions characterised by joint contractures or arthrogryposis, pterygia or webbing across 
the joint and a variety of congenital anomalies. This spectrum of conditions has been 
considered in the context of congenital anomalies. Particular attention has been given to joint 
contractures, a consistent feature of this group of conditions, as the causes of arthrogryposis 
provide important insights into the underlying mechanisms for the clinical phenotype. This 
information can be also be utilized in selecting candidate genes for further study and in 
understanding the biological basis of disease.  
 
This chapter reviews the literature up to 2010 when the clinical and laboratory work had been 
completed and the MD research thesis write-up commenced. 
  
1.2 Congenital Anomalies 
 
The word “congenital” is derived from the Latin “congenitus” first used in 1796, meaning 
present or existing at the time of birth. Babies may be born with a variety of structural 
developmental abnormalities known as congenital anomalies, congenital abnormalities, 
congenital malformations or birth defects. During the first 14 days after conception insults or 
injuries to the embryo are either repaired or result in an early fetal demise and miscarriage of 
the pregnancy.  Embryopathies can arise up to around 8 weeks post conception when the 
rapidly developing embryo is especially vulnerable to damage because of the large numbers 
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of mitotic cell divisions. Fetopathies result from damage to the fetus after this time. However 
most organs, except for the brain, are formed by this time and are therefore less susceptible to 
injury.  Defects in fetal development may be due to environmental, genetic, multifactorial or 
unknown factors.  A recognisable pattern of developmental problems is referred to as a 
syndrome.  
 
Congenital anomalies can arise through a variety of mechanisms. There are various 
classifications for congenital abnormalities. A primary abnormality is due to an inherent 
defect that affects organ development. Primary abnormalities can be divided into gene 
defects, which cause 7.5% of congenital anomalies, and chromosome aberrations, which 
account for approximately 0.5%. Secondary abnormalities are caused by factors that adversely 
affect development before birth. The development of a secondary congenital abnormality is 
influenced by the health of the mother, the nature of the toxin or insult, the timing of the 
damage and the genetic background of the fetus. Multifactorial anomalies are due to 
environmental factors acting on genetically susceptible individuals. Neural tube defects 
ranging from spina bifida through to anencephaly have been associated with genetic as well as 
environmental factors. The high recurrence risk for siblings of those with a neural tube defect 
supports a role for genetic susceptibility (Detrait et al., 2005, Harris and Juriloff, 2007) and 
the prevention and reduced recurrence of neural tube defects with preconception folic acid 
supplementation is evidence of the ameliorating effect of an environment factor (Blencowe et 
al., 2010).  
 
Review of the likely mechanisms leading to a congenital anomaly can be helpful in 
elucidating the underlying cause of that developmental abnormality, providing information 
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about the aetiology and likelihood of recurrence for families as well as enabling classification 
of the data for the collection and public health monitoring purposes. 
  
1.2.1 Mechanisms of congenital anomalies 
 
Congenital anomalies can arise through four different mechanisms: malformation, disruption, 
deformation and dysplasia. 
 
1.2.1.1 Malformations 
  
Major malformations arise in the embryonic period of development, between two and eight 
weeks of gestation, and are due to inherent differences in the development of a tissue. These 
congenital anomalies can be due to altered processes in the development of the egg, sperm or 
the embryo which may occur before, during or after fertilisation. They can be due to single 
gene disorders as well as chromosome abnormalities.  
 
A chromosome disorder may be suspected in an affected infant because of the presence of 
multiple congenital anomalies that may be accompanied by global developmental delay. A 
condition with recognisable pattern of developmental abnormalities is referred to as a 
syndrome. Examples include Down syndrome or trisomy 21, Edward syndrome or trisomy 18 
(Edwards et al., 1960) and Patau syndrome or trisomy 13 (Patau et al., 1960), in each of 
which a whole extra chromosome is present. Smaller chromosome imbalances, 
microduplications or microdeletions, are increasingly detected due to the availability of higher 
resolution chromosome testing (microarrays) and new phenotypic associations are being 
described. An example is the 3q29 microdeletion syndrome (Willatt et al., 2005). Single gene 
disorders may affect the development of one or more organ. For example Holt-Oram 
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syndrome due to autosomal dominant mutations in TBX5 is characterised by congenital heart 
disease and radial ray abnormalities (Mori and Bruneau, 2004).   
 
1.2.1.2 Disruption  
 
Disruption is the adverse affect or interruption of the usual developmental processes by 
extrinsic factors and can arise at any time in the fetal period, commencing at eight weeks of 
gestation. An example is the loss of peripheral elements usually of the limbs due to amniotic 
bands. Approximately 10-15% of congenital anomalies are estimated to be the result of 
adverse environmental factors on prenatal development, the majority of which are due to 
maternal disease states and less than 1% to external agents such as drug or chemical exposure 
(Brent and Beckman, 1990). Other external factors which may disrupt the usual 
developmental processes include teratogens such as alcohol, drug treatments such as sodium 
valproate for epilepsy, diabetes and infections such as cytomegalovirus and rubella. 
Teratogens can have a wide range of affects depending on the timing and nature of the 
exposure. Teratogens can cause reduced fertility, intrauterine growth retardation, structural 
abnormalities, intellectual disability as well as pregnancy loss and fetal death (Gilbert-
Barness, 2010).  
 
1.2.1.3 Deformation sequence  
 
This is the response of normal tissue to an unusual mechanical force that occurs in the fetal 
period of development and is more frequent in the third trimester due to greater fetal 
constraint. A sequence of fetal consequences can arise due to a single malformation or 
mechanical factor in the fetus or the mother. Potter’s sequence has an incidence of 1 in 4000 
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births. Oligohydramnios in utero due to fetal renal agenesis, polycystic kidneys or an 
obstructive uropathy results in the typical constellation of features which includes a 
recognisable facial appearance and severe usually fatal respiratory insufficiency due to 
pulmonary hypoplasia (Potter, 1946). Pierre-Robin sequence has an incidence of 
approximately 1 in 8500 live births (Bush and Williams, 1983) and is characterised by a triad 
of micrognathia, cleft palate and retroglossoptosis (Robin, 1994). Although the causes of the 
Pierre-Robin sequence are very heterogeneous, this triad of anomalies arises from a single 
malformation. The mechanical obstruction caused by mandibular hypoplasia results in the 
tongue being positioned high in the oral cavity preventing closure of the palatal shelves. 
Delay in the neurological maturation of the tongue musculature may contribute to the Pierre 
Robin sequence. This is supported by self-correction with time in the majority of cases. Fetal 
akinesia deformation sequence (FADS) is another example of a deformation sequence with an 
estimated incidence of 1 in 15,000 (Bayat et al., 2009). A recognisable pattern of 
developmental features attributable to fetal immobility includes joint contractures, pulmonary 
hypoplasia and a cleft palate. A lack of swallowing movements may also be associated with 
maldevelopment of the abdomen and gut in some patients and a dysmorphic appearance 
including hypertelorism. 
 
1.2.1.4 Dysplasia  
 
Dysplasia or congenital abnormalities of tissue development or differentiation may affect 
several organs at the same time. Examples are skeletal syndromes in which there may be a 
dysplasia of the developing bone or cartilage. However the cause may not be identified as it 
may be a non-specific effect. 
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1.2.2 Consequences of congenital abnormalities 
 
Isolated congenital anomalies or multiple congenital anomalies affecting more than one 
system of the body may be present. There may be major or minor abnormalities. Minor 
congenital anomalies have no serious medical consequences whilst major anomalies may 
require medical or surgical treatments or result in early demise. Major congenital anomalies 
occur in 2-3% of fetuses and newborns. After immaturity they are the second most common 
cause of infant death accounting for 0.1% of deaths in liveborn children (Office for National 
Statistics, 2010). Following prenatal detection of fetal anomalies, a fifth of cases are lost 
through pregnancy termination, die after 20 weeks of gestation, are stillborn or die soon after 
birth.  Approximately 80% are liveborn (Dolk et al., 2010). Chromosome abnormalities are 
identified in 0.36% of births, but account for almost a third of fetal deaths and a congenital 
anomaly diagnosed after 20 weeks is present in almost half of pregnancy terminations.   
 
In the non chromosomal group, congenital heart defects occur most frequently in 0.63%. 
Cardiac disease is the commonest cause of death from a congenital anomaly. Limb anomalies 
are the next most frequent congenital anomaly occurring in about 0.36%, however unlike 
congenital heart disease they do not usually result in death. Urinary tract anomalies are 
identified in 0.28% and nervous system anomalies in 0.22%. Congenital anomalies in other 
systems occur less frequently (Office for National Statistics, 2010, (Dolk et al., 2010).  
 
Particular attention has been given below to limb anomalies, as these are a major component 
of MPS / FADS, the subject of this research study. 
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1.2.3 Limb anomalies 
 
Limb defects may be detected antenatally or immediately after birth. This group includes a 
wide variety of limb anomalies, such as upper and lower limb reduction defects, polydactyly 
and syndactyly, as well as arthrogryposis multiplex congenita and isolated joint contractures 
such as congenital clubfoot and congenital hip dysplasia and dislocation. These conditions 
occur with widely differing frequencies with complete absence of a limb occurring in 0.18 per 
10,000 pregnancies whereas congenital club foot is recorded in 9.8 per 10,000 pregnancies 
(Dolk et al., 2010).  Limb defects may be isolated or may occur with multisystem 
involvement as part of a syndrome. They may occur as a consequence of environmental or 
genetic conditions or as part of a deformation sequence. An example is the multiple joint 
contractures that occur as part of the Fetal Akinesia Deformation Sequence (FADS). Joint 
contractures / arthrogryposis are a major component of the Multiple Pterygium Syndromes 
(MPS) / FADS spectrum of conditions. 
 
1.3 Limbs and joints 
As development of the limbs and joints occurs early in gestation, genetic factors and very 
early environmental insults incur the maximal impact. 
 
1.3.1 Limb development 
 
The upper limb bud appears at 26 days of gestation and is followed on the 28th day by the 
lower limb bud. The limb buds are mainly comprised of mesenchymal cells which 
differentiate into the various limb tissues. Cells derived from somites form a distinct 
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population that become the myoblasts. Neural elements later invade the developing limb bud. 
The apical ectodermal ridge is a specialised layer of ectoderm which drives the differentiation 
of mesenchymal cells. Limb structures are formed in a proximal to distal direction, for 
example the humerus and femur before the digital structures. Development and maturation of 
the bones, muscles and nerves of the limbs occurs in parallel throughout gestation. 
 
Early on in development the preaxial borders of the upper limbs face cranially but are 
medially positioned by the end of the embryonic period.  In the lower limbs the soles of the 
feet are medially positioned in a “praying” stance however during the fetal and early postnatal 
period the foot position is modified so that the sole of the foot can rest on the ground. The 
future skeleton is laid down as a collagen template in the first month of fetal life onto which a 
mineralised bone is deposited from the second month. The process of chondrogenesis occurs 
in an oxygen poor environment whereas osteogenesis requires a good supply of oxygen. 
There are important differences between embryonic and postnatal bone. Embryonic bone 
contains irregularly arranged collagen fibres, is highly mineralised and contains a large 
number of osteocytes whereas lamellar bone is less mineralised, contains fewer osteocytes 
and gradually covers the connective tissue vascular spaces of the embryonic bone. All 
primary bone is remodelled by the age of 2 years. Ossification of the long bones begins in the 
perichondral region and proceeds distally. Ossification of the vertebrae occurs from three 
primary ossification centres and commences in the lower thoracic vertebrae from around the 
eighth week and proceeds cranially and caudally (Royer et al., 1981). Skull bones are the last 
to fuse, with some cranial sutures only fusing in adult life (Enlow et al., 1986). 
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Multinucleated muscle cells appear at about five weeks of gestation and early muscle fibres 
are present from around the eleventh week. By about 20 weeks most muscle fibres appear 
similar to adult muscle. Although initial muscle development occurs in the absence of nerve 
innervation, neurological stimulus is required from 20 to 24 weeks of gestation to enable 
further muscle development and differentiation. The two muscle fibre types, slow and fast 
twitch fibres, cannot be distinguished before 18 to 20 weeks of gestation. Slow twitch fibres 
are present in early development whilst fast twitch fibres increase after week 26 and 
approximately similar numbers of both fibre types are present at term. Muscle cells increase 
in number rather than size during the first 26 weeks. After this time the cell size increases and 
the cell number increases more slowly. Growth occurs by hypertrophy of existing fibres once 
muscle differentiation is complete.  
 
From around week 10 primitive nerve fibres are found in the vicinity of the muscle fibres. 
Myoneural junctions are formed by week 11 and recognisable motor end plates can be 
identified. During development the several motor nerves innervating a single muscle fibre are 
replaced by a single axon. The precursor to the muscle spindle, the spindle nerve fibre 
complex can already be identified between 9 and 10 weeks of gestation in human embryos 
(Deriu et al., 1996).  
 
 
1.3.2 Joint classification 
 
Joints are derived from mesenchyme. There are three types of joint, fibrous joints, 
cartilaginous joints and synovial joints, each with different mechanical properties adapted to 
their function in the body. In the skull, the joints between the cranial sutures form as the 
mesenchyme is transformed into a dense fibrous connective tissue. The cranial sutures allow 
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for slight movement critical during childbirth and for brain growth in early childhood 
however these joints later become rigid to provide better protection for the brain. In 
cartilaginous joints the mesenchymal tissue between the bones becomes cartilage. 
Cartilaginous joints allow more movement between the joints than fibrous joints, but are less 
mobile than synovial joints. Examples are the manubrio-sternal joint which enables effective 
upward and outward chest movement that occurs with each breath, the intervertebral discs 
allowing spinal mobility and the pubic symphysis assisting delivery of the head during 
childbirth. The third type of joint is the synovial joint. These joints are the most mobile and 
allow the widest range of movement, but have the least joint stability. This is particularly well 
illustrated by the rotatory motion that can be achieved by the hip. Other synovial joints with a 
lesser range of movement include the elbow, the knee and the interphalangeal joints. Synovial 
joints are comprised of complementary shaped surfaces with an articular cartilage covering. 
The joint has a synovial lining and is encased in a synovial capsule. Stability and joint 
movement is provided by the ligaments in and around the joint. The various components of 
the joint are adapted to their particular roles. The articular cartilage is stratified into layers. 
The superficial zone produces lubricants to enable smooth joint movements. The long flat 
cells are embedded in a collagenous matrix parallel to the articular surface. The cells in the 
middle zone are round and ordered vertically. They give the material its toughness. The cells 
in the bottom zone interface between the articular cartilage and the underlying bone. The cells 
here are large and also involved in matrix production (Archer et al., 2003).  
 
1.3.3 Joint development 
 
The mammalian skeleton in embryos is formed from a continuous cartilaginous structure. 
Histologically the joint forms from a layer of avascular, compact mesenchymal tissue that 
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interrupts the adjacent cartilage. This interzone region expresses growth and differentiation 
factors essential for joint development, as removal of the interzone cells results in expansion 
and union of the cartilaginous segments. The cells in the interzone region are flat and tightly 
bound at right angles to the limb (Holder, 1977, Storm and Kingsley, 1996). These cells have 
been shown to be joint progenitor cells for a variety of tissues including articular cartilage, 
synovial lining and ligaments within the joint that remain functional in the adult. However 
other cells need to migrate from the surrounding tissues into the developing joint to enable 
joint development to proceed (Pacifici et al., 2006, Decker et al., 2014). A summary of the 
sequence of events in joint formation are outlined below in Fig 1. 
 
 
 
 
Figure 1: Generalised model of joint development 
(Taken from Genesis and morphogenesis of limb synovial joints and articular cartilage, Decker et al., 
2014). 
 
 
The components of the bone mesenchyme are continuous throughout the structure. Unknown 
upstream mechanisms determine the site of future joint development. Initial formation of the 
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mesenchymal interzone cell population occurs through the expression and migration of Gdf5 
positive mesenchymal cells in the interzone to form both the cartilage and fibrocartilagenous 
elements of the joint. This process is dependent on the Noggin, Wnt4/Wnt9a, Tgfbr2, β-
catenin, TAK1 and Ext2, as defective joint formation and cartilage fusion due to early or 
excess chondrocyte differentiation have been observed in mice lacking these genes (Brunet et 
al., 1998, Spater et al., 2006, Spagnoli et al., 2007, Gunnell et al., 2010, Mundy et al., 2011). 
Differential expression of Tgfbr2 and matrillin-1 influences the development of the articular 
chondrocytes, ligaments and other joint structures as well as population of progenitor cells for 
repair and regeneration. Joint formation and development of the growth plate and bone shaft 
are closely coordinated. This is illustrated by the joint fusion seen in mice lacking ihh 
expression (St-Jacques et al., 1999) and the marked joint, meniscal and growth plate 
abnormalities in mice lacking the chondrogenic genes Sox5 and Sox6 (Dy et al., 2010). Other 
local regulators of joint formation include Sox11, Osr1 and Osr2 zinc transcription factors 
(Kan and Tabin, 2013, Gao et al., 2011). The fluid filled synovial joint space is formed by 
cavitation later in gestation and in early postnatal life. Immobilisation inhibits joint cavitation, 
whereas the earlier developmental processes in the joint such as specification of the cells, 
limb patterning and the growth of the joint occur even in the absence of muscular activity 
(Lamb et al., 2003), thus other genes are likely to drive joint cavitation. It has been suggested 
that the joint cavity appears by programmed cell death (Abu-Hijleh et al., 1997) however 
there is little evidence to substantiate this (Pacifici et al., 2005, Pitsillides and Ashhurst, 
2008).  
 
The development and growth of bones and joints is a dynamic process modified by 
movement. Load bearing movement significantly increased adult bone strength. This effect 
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has been shown to be more marked in slow growing animals. Bones with inherently slower 
rates of growth, which may be due to genetic factors, are more responsive to extrinsic stimuli 
(Patterson et al., 1986, Fleming et al., 1994). Experimental evidence has shown that 
movement has an important role in the formation and maintainance of the joint cavity. A lack 
of embryonic joint movement prevents formation of joint cavities and causes regression of the 
joint cavities that have been formed and fusion of opposing cartilaginous joint elements 
(Osborne et al., 2002). Nerve damage resulting in immobilization inhibits the formation of the 
joint cavity (Osborne et al., 2002) whereas movement stimulates the establishment of joint 
cells and joint lubricants (Dowthwaite et al., 2003). However experiments with agents causing 
irreversible neuromuscular blockade and muscle spasticity, and thus a continuous static load 
on the joints, have been shown to inhibit the formation of joint cavities and promote joint 
fusion (Kavanagh et al., 2006). In addition, mouse embryos without contracting muscles fail 
to activate Wnt/β-catenin signalling and develop normal joints. As certain joints appear to be 
more susceptible to this effect, there may be a differential joint response. This may due to a 
different mechanism and pattern of signalling molecules depending on the joint (Kahn et al., 
2009). Factors such as the joint function and the timing of the immobility may be produce 
varying affects on the different joint types. In addition, earlier developmental processes such 
as limb outgrowth and limb patterning occur independently of limb movement and muscle 
activity and may be determined by underlying genetic programming (Lamb et al, 2003). 
Overall, although the formation of limb joints is a complex interplay between the cells in and 
adjacent to the interzone, the growth plate and many transcription and signalling factors at 
various stages of development, mechanical factors such as the action of skeletal muscles 
during movement are also essential for this process.  
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1.4 Joint contractures and arthrogryposis 
 
Joint contractures can occur as an isolated finding or in association with a variety of 
congenital abnormalities as a component of a syndrome or in utero deformation sequence. 
Isolated joint contractures affecting a single joint type are common and may be present in 
healthy newborns. Conditions such as congenital talipes equinovarus or congenital dislocation 
of the hips are seen in more than 1% of newborns. There may be family history of similar 
joint contractures for example a positive family history of developmental hip dyplasia has 
been observed in over 20% of children requiring treatment for this condition (Marks et al., 
1994). This inherited predisposition may be due to factors such as joint laxity or the skeletal 
development in the family. Environmental factors such as oligohydramnios and a breech 
presentation at birth are well recognised risk factors for congenital hip dislocation (Chan et 
al., 1997). Joint contractures may occur in association with other congenital abnormalities in a 
wide range of genetic syndromes notably Edward syndrome (Trisomy 18) and cerebro- oculo-
cutaneous-skeletal syndrome (COFS), a neurodegenerative autosomal recessive disorder 
which also includes features of microcephaly, congenital cataracts, severe mental retardation 
and a dysmorphic facial appearance (Pena and Shokeir, 1974). They may occur as a result of 
central or peripheral nervous system insults, muscle disorders as well as environmental 
exposure to congenital infection. Progressive joint contractures may result from disease 
processes such as inflammatory myositis which affect the soft tissue components around the 
joint.  
 
Arthrogryposis multiplex congenita or multiple joint contractures are less common. The 
incidence has been estimated to be 1 in 3000 live births (Fahy and Hall, 1990, Hall, 1985), 
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however a Swedish study suggested a birth prevalence of 1 in 5000 live births for multiple 
congenital contractures (Darin et al., 2002). AMC may be detected on ultrasound scan in 
utero, particularly if there is extensive joint involvement, congenital abnormalities and severe 
associated fetal akinesia. For the incidence of joint specific congenital contractures see Table 
1.  
 
All congenital contractures  1/100 – 1/250  
Talipes equinovarus  
(Danielsson, 1992, Paton et al., 2010, 
Bridgens and Kiely, 2010) 
1-2/1000 
Congenital dislocated hips 
(Sewell et al., 2009) 
1-3/100  
AMC  
(Hall, 1985) 
(Darin et al., 2002) 
1/3000  
 
Table 1: Incidence of congenital contractures. 
(Adapted from Arthrogryposis: A Text Atlas, edited by Staheli, Hall, Jaffe, Paholke, Cambridge 
University Press, 1998). 
 
  
1.4.1 Aetiology of arthrogryposis  
 
Arthrogryposis is a descriptive term derived from Greek in which ″Arthron″ means joint and 
″Grypos ″ means curved. Thus arthrogrypotic joints are fixed in a curved position. 
Arthrogryposis multiplex congenita (AMC) is defined by the presence of multiple joint 
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contractures affecting more than one region of the body that are present from birth. Fetal 
movement is essential for normal joint formation and arthrogryposis occurs when there is 
decreased joint movement in the fetus. During development, whole body movements in the 
fetus commence from around 7-8 weeks of gestation (de Vries et al., 1982). Upper limb 
movements begin at about 9 weeks and lower limb movements start from around 10 weeks of 
gestation (Luchinger et al., 2008). Contractures result from factors that inhibit normal fetal 
movement and are associated with increased connective tissue around the joints. Immobilised 
joints surfaces become flattened, further limiting the range of joint movement. More severe 
contractures at birth are associated with an earlier onset and longer duration of fetal akinesia 
(Moessinger, 1983, Hall, 1986).   
 
The aetiology of AMC is very heterogeneous and diverse (see figure 2), thus the character of 
the joint contractures, the associated features, prognosis, inheritance and subsequent 
recurrence risks vary widely. Fetal hypokinesia or akinesia can be due to factors in the mother 
or in the fetus. It can be due to extrinsic or environmental factors such severe fetal constraint 
due to lack of available space as well as or intrinsic or genetic factors, with arthrogryposis 
being a recognised component of more than three hundred conditions (Hall et al., 1982a). The 
affected limbs are typically cylindrical with thin overlying subcutaneous tissue, an absence of 
skin creases and the muscle may appear atrophic or absent (Wynne-Davies and Lloyd-
Roberts, 1976). As well as rigidity of the affected joints there may be joint dislocations most 
frequently affecting the hips followed by the knees. Involvement of the temporomandibular 
joint frequently results in associated limited mouth opening or trismus.  The contractures 
themselves may have different characteristics depending on whether they are due to intrinsic 
or external factors. In general, joint contractures caused by intrinsic factors are symmetrical 
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with tightness of the overlying skin and a lack of flexion creases over the joints. Additional 
accompanying features may include polyhydramnios and webbing across the joints. 
Contractures due to external forces may be associated with position limb anomalies, normal 
or prominent flexion creases lax or tight skin (Navarro et al., 2004). A sub-type of Ehlers-
Danlos syndrome has been described in which individuals have recognisable craniofacial 
characteristics, multiple congenital contractures, progressive joint and skin laxity, and 
multisystem fragility-related manifestations (Kosho et al., 2010). The most common cause of 
arthrogryposis is amyoplasia, accounting for a third of patients with AMC. A further third 
have an underlying central nervous system abnormality causing their arthrogryposis and the 
remaining third are due to a variety of disorders, see Fig 2. It has been estimated that a 
specific cause for the arthrogryposis can be identified in half of patients (Fahy and Hall, 
1990).  
 
 
Figure 2: Aetiology of Congenital Contractures 
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1.4.1.1 Amyoplasia 
 
Amyoplasia literally meaning a lack of muscular growth is the commonest cause of AMC, 
with an incidence of approximately 1 in 10,000 live births. In three quarters of patients all 
four limbs are involved and there is symmetric involvement of the upper and lower limbs in 
60-80% of patients (Sells et al., 1996, Hall et al., 1983). However, less commonly there is 
involvement of the upper or lower limbs or an asymmetric pattern of limb involvement 
(Vanpaemel et al., 1997, Hall et al., 1983). Typically the shoulders slope downwards and are 
internally rotated and adducted. The elbows are usually extended and wrists are flexed and 
deviated to the ulnar side. Accompanying dimpling may be observed over the affected joints. 
There is fibrotic replacement of the muscle and a glabella haemangioma may be present. 
Intellectual development is normal. There is usually a good response to early physiotherapy. 
Amyoplasia is almost certainly not genetic and may be due to vascular compromise in early 
development. This is supported by the occurrence of amyoplasia in only one sibling of several 
monozygotic twin pairs, and the association of trunk wall defects and congenital bowel 
anomalies such as gastroschisis and bowel atresias in around 10%. Amyoplasia  usually 
occurs sporadically and has a low recurrence risk (Hall et al., 1983).  
 
 
1.4.1.2 Maternal Factors 
 
Arthrogryposis may be due to factors in the mother. Myasthenia gravis is an acquired 
autoimmune condition. It most commonly presents in females during adolescence or early 
adulthood and is characterised by progressive weakness and fatiguability of the voluntary 
muscles. It is caused by antibodies binding to nicotinic acetylcholine receptor (AChR) at the 
neuromuscular junction resulting in loss of these receptors (Drachman, 1994). Conditions 
such as maternal myasthenia gravis cause arthrogryposis by the transfer of maternal  
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acetylcholine receptor antibodies through the placenta to the fetus. IgG antibodies to the adult 
acetylcholine receptor subunit causes transient myasthenic syndrome symptoms in about 10% 
of newborns that subside after birth with the decrease in maternal IgG antibody levels (Namba 
et al., 1970). However the earlier passage of maternal antibodies to the fetal acetylcholine 
receptor or to the MuSK receptor, also involved in neurotransmission across the synapse, 
impairs early fetal movement and causes abnormal joint and muscle development (Vincent et 
al., 1995). Due to the presence of antibodies to the fetal neuromuscular junction components, 
asymptomatic women with myasthenia gravis can have children with arthrogryposis multiplex 
congenital and fetal akinesia sequence (Brueton et al., 2000).  Decreased fetal movement and 
joint contractures can occur in association with maternal myotonic dystrophy (Stratton and 
Patterson, 1993, Robin et al., 1994). Other maternal causes of arthrogryposis include maternal 
hyperthermia in pregnancy caused by abnormal nerve growth or nerve migration (Reid et al., 
1986, Edwards, 1986), limited space due to structural uterine abnormalities or multiple births 
and maternal drug ingestion or vascular compromise (Hall, 1996). Congenital fetal infection 
due to maternal cytomegalovirus infection may result in arthrogryposis with additional 
teratogenic features due to the viral infections. Other maternal infections in pregnancy, such 
as rubella, varicella and coxsackie virus infections can also cause multiple joint contractures 
through central or peripheral nerve destruction (Konstantinidou et al., 2007, Hall and Reed, 
1982). Maternal diabetes and multiple sclerosis have been associated with the presence of 
joint contractures, although the mechanism is unknown (Livingstone and Sack, 1984). Severe 
bleeding in pregnancy or a failed pregnancy termination has been reported in association with 
multiple joint contractures, presumably due to an interruption to the blood supply to the 
developing joints (Hall, 1996, Wynne-Davies and Lloyd-Roberts, 1976). It is important to try 
to identify the underlying cause of the arthrogryposis, as there may be particular health 
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surveillance recommended for affected patients. This information is also important to inform 
families of the recurrence risk, which may vary considerably depending on the underlying 
cause.  
 
1.4.1.3 Fetal Factors 
 
As fetal movement is essential for normal joint development, conditions in the fetus that 
cause fetal hypo or akinesia can result in joint contractures and other features of the fetal 
akinesia deformation sequence (FADS). The intact motor pathway initiates and controls 
movement. Electrical nerve impulses originating from the primary motor cortex in the brain 
mainly pass along upper motor neurone to the contralateral side of the spinal cord where they 
synapse with the anterior horn cell. This electrical signal is transmitted down through the 
lower motor neurone and is chemically transmitted across the neuromuscular junction. On 
reaching the motor end plate, the nerve impulse causes the muscle to contract.  Therefore, any 
factors that interrupt this pathway can potentially cause fetal akinesia and arthrogryposis (see 
Figure 2).  AMC in the fetus is due to neurogenic factors in 80-90% (Banker, 1985, Hageman 
et al., 1987, Vuopala et al., 1994). This may include problems with the development of the 
brain, the spinal cord or the peripheral nerves. It has been estimated that the underlying cause 
of fetal akinesia deformation sequence can be determined with extensive neuropathological 
studies of the brain, spinal cord and muscles in about 50% of those affected (Witters et al., 
2002). 
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Figure 3: Motor nerve pathway from brain to muscle.  
Defects in components along this pathway can result in fetal akinesia and arthrogryposis. 
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Developmental brain abnormalities 
 
Brain abnormalities are the commonest cause of multiple joint contractures. A wide variety of 
brain pathologies can cause reduced or absent fetal movement. A developmental brain 
abnormality (Brodtkorb et al., 1994, Vuopala et al., 1994, Fedrizzi et al., 1993) may occur as 
an isolated problem or as part of a syndrome and is usually a sporadic occurrence. In general, 
the mortality, morbidity and developmental progress in this group is less favourable (Darin et 
al., 2002). Major structural brain abnormalities such as anencephaly and holoprosencephaly 
can be associated with arthrogryposis (Morse et al., 1987, Hockey et al., 1988). 
Arthrogryposis and seizures may be seen with neuronal migration disorders such bilateral 
perisylvian polymicrogyria (Kuzniecky et al., 1993, Gropman et al., 1997, Poduri et al., 
2010). A lethal familial fetal akinesia syndrome has been identified in association with 
lissencephaly (Encha Razavi et al., 1996). Structural brain anomalies can be associated with 
joint contractures and there is evidence that CNS hypoxia or injury may be associated with 
secondary muscle changes and fetal akinesia (Rudzinski et al., 2010).  
 
Spinal cord pathology 
 
Anterior horn cell pathology occurs in Spinal Muscular Atrophy (Burglen et al., 1996). 
Homozygous SMN1 deletions associated with a low SMN2 copy number have a severe 
presentation. Patients may be born with generalised oedema, multiple joint contractures, 
micrognathia and a high arched palate, and die in the neonatal period or in early infancy 
(Devriendt et al., 1996, Garcia-Cabezas et al., 2004). Mutations in the Ubiquitin activating 
enzyme 1 (UBE1) have been identified with loss of anterior horn cells in severe lethal X-
linked SMA. Patients with this condition have multiple joint contractures, hypotonia, 
respiratory insufficiency and die in infancy (Ramser et al., 2008).   
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The Finnish lethal congenital contractural syndrome 1 (LCCS1), the most severe human 
motor neurone disease, is characterised by marked loss of spinal motor neurones and fetal 
akinesia. Severe fetal immobility may be detected at about 13 weeks of gestation and is 
associated with fetal hydrops, multiple joint contractures, pterygia and lung hypoplasia.  On 
neuropathological examination there is lack of anterior horn cells and severe atrophy of the 
ventral spinal cord. Skeletal muscle is severely hypoplastic or almost absent. It is due to 
autosomal recessive mutations in the mRNA export mediator GLE1, indicating the critical 
role of mRNA processing in the development and survival of anterior motor neurones 
(Nousiainen et al., 2008).  
 
Lethal congenital contractural syndrome 2 (LCCS2) and LCCS3 have been described in 
Israeli-Bedouin families. Affected neonatal LCCS2 patients have decreased fetal movements, 
multiple joint contractures, severe muscle wasting and a neurogenic bladder due to atrophy of 
the anterior horn cells of the spinal cord. Homozygous mutations in Epidermal growth factor 
receptor 3 (ERBB3) have been identified (Narkis et al., 2007b). LCCS3 is similar to LCCS2, 
however the bladder abnormalities are not present. It is due to homozygous mutations in 
phosphatidylinositol-4-phosphate-5-kinase, type 1, gamma (PIP5K1C) (Narkis et al., 2007a). 
 
Abnormalities of the peripheral nerves 
  
Congenital hypomyelination neuropathy due to deficiency of myelin proteins has been 
observed in arthrogryposis multiplex congenita (Boylan et al., 1992). Congenital 
hypomyelination neuropathy or amyelination of the peripheral nerves is associated with 
multiple joint contractures, respiratory distress and infant demise (Gabreels-Festen, 2002). 
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The genetic basis of this condition is currently unknown, although genes known to cause 
progressive hypomyelination have been suggested as possible candidates. 
 
Neuromuscular junction pathology 
 
Neuromuscular junction disorders can be congenital or acquired. Examples of acquired 
disease include myasthenia gravis and Lambert-Eaton myathenic syndrome, both of which are 
due to autoimmune conditions causing antibodies to specific nerve components and muscle 
ion channels. Fetal akinesia and arthrogryposis secondary to maternal myasthenia gravis is 
discussed in section 1.4.1.2 maternal factors.  
 
The congenital myasthenic syndromes (CMS) are a rarer group of inherited conditions with an 
estimated prevalence of 1 in 500,000 (Millichap and Dodge, 1960) that can also be associated 
with multiple joint contractures (Vajsar et al., 1995). Congenital myasthenic syndromes are 
characterised by muscle weakness and fatigability due to impaired transmission of nerve 
impulses across the neuromuscular synapse.  Fluctuating extraocular, bulbar and respiratory 
symptoms are typically present. The phenotypic spectrum varies from a rare severe prenatal 
onset of arthrogryposis and neonatal respiratory compromise through to weakness present at 
birth or in early childhood, feeding difficulties, ptosis, abnormal eye movements and delayed 
motor milestones usually in the absence of joint contractures (Brownlow et al., 2001, Beeson 
et al., 2003). This group of conditions is genetically heterogeneous and most frequently due to 
autosomal recessive mutations in acetylcholine receptor pathway genes however autosomal 
dominant gene mutations may be implicated. CMS can be due to abnormalities of ACh 
release, AChR number or function as well as acetylcholinesterase activity. Mutations in the 
postsynaptic AChR genes may alter the kinetics of the response to ACh in the synapse and 
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can result in fast and slow channel phenotypes. In the fast channel syndromes there is brief 
infrequent ion channal activation resulting in reduced postsynaptic acetylcholine receptor 
opening times and thus a reduced response to acetylcholine. In slow channel syndrome there 
is prolonged opening of the acetylcholine receptors, resulting in a depolarising block of the 
muscle acion potential. Fast channel syndromes are due to autosomal recessive loss of 
function mutations whereas slow channel syndromes are caused by autosomal dominant gain 
of function mutations, (Ohno et al., 1997, Shen et al., 2005).   
 
The genes most commonly implicated in CMS are CHRNE, CHAT, COLQ, DOK7, GFPT and 
RAPSN. Mutations in CHRNE, which encodes the epilson subunit of the adult acetylcholine 
receptor, are present in about half of those affected with CMS (Beeson et al., 2005). 
Mutations in RAPSN account for around 15% of cases (Gaudon et al., 2010). CMS is 
diagnosed from the clinical history, characteristic electrophysiology showing a decremental 
response of the compound muscle action potential to low-frequency stimulation, a positive 
response to anti-cholinesterase inhibitors and the absence of acetylcholine receptor antibodies. 
Although individuals affected with this condition have the hallmark features of CMS, 
particular distinguishing features in the clinical presentation may point to the underlying 
genetic aetiology. For example, autosomal recessive mutations in DOK7 are associated with a 
predominantly limb girdle pattern of weakness, ptosis but no external ophthalplegia (Palace et 
al., 2007). Recessive mutations in the acetylcholine receptor subunit CHRND and RAPSN 
have been detected in children born with arthrogryposis (Brownlow et al., 2001, Burke et al., 
2003, Banwell et al., 2004).  
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The multiple pterygium syndromes can also result from neuromuscular dysfunction as 
discussed in Chapter 1.5. 
 
Primary muscle conditions  
 
Muscle conditions such as the congenital muscular dystrophies, congenital myopathies and 
myositis are estimated to account for 5-10% of the cases of fetal akinesia (Banker, 1985). 
Central core disease may be due to autosomal recessive and autosomal dominant RYR1 
mutations (Romero et al., 2003). Multi-minicore disease caused by SEPN1 gene mutations 
can result in reduced prenatal fetal movements, polyhydramnios and arthrogryposis 
(Jungbluth et al., 2000, Ferreiro et al., 2000). A severe form of nemaline myopathy with 
absent spontaneous movement, arthrogryposis and death in early life has been described with 
autosomal recessive NEB mutations (Wallgren-Pettersson et al., 2002) and ACTA1 mutations 
(Garcia-Angarita et al., 2009, Stenzel et al., 2010). (Stenzel et al., 2010) 
 
X-linked myotubular myopathy caused by mutations in MTM1 may present with reduced fetal 
movements and poyhydramnios. However, these patients usually have severe hypotonia and 
generalised muscle weakness (Laporte et al., 1996, Chang et al., 2008).  Autosomal recessive 
mutations in Contactin-1 (CNTN1) have been identified in a consanguineous Egyptian family 
with fetal akinesia and lethal congenital myopathy. Contactin-1 is expressed in the central and 
peripheral nervous systems and the neuromuscular junction. However, abnormal localisation 
of contactin-1 at the skeletal muscle sarcolemma is associated with secondary 
dystroglycanopathy due to loss of beta2-syntrophin and alpha-dystrobrevin.  Thus, this 
condition may be considered as a congenital myopathy or a neuromuscular junction disorder 
(Compton et al., 2008). 
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Connective tissue abnormalities 
 
Connective tissue conditions such as restrictive dermopathies can lead to fetal akinesia, joint 
fixation and arthrogryposis through collagenous thickening of the joint capsule (Happle et al., 
1992).  Restrictive dermopathies may be due to autosomal dominant mutations in LMNA or 
more frequently to autosomal recessive mutations in ZMPSTE24 (Navarro et al., 2004, 
Navarro et al., 2005, Smigiel et al., 2010). Autosomal dominant FBN2 mutations can cause 
congenital contractural arachnodactyly or Beals syndrome, which can be associated with 
severe joint contractures, a characteristic crumpled appearance of the ears and a long, thin 
body habitus (Beals and Hecht, 1971, Ramos Arroyo et al., 1985, Putnam et al., 1995). 
Excessive joint laxity occurring in collagen disorders such as Larsen syndrome can be 
associated with congenital joint contractures, particularly talipes eqinovarus, and joint 
dislocations (Larsen et al., 1950, Krakow et al., 2004).Variants of Ehlers Danlos (EDS) 
syndrome such as CHST14-related EDS Kosho type can also present with a combination of 
joint flexibility and contractures (Miyake et al., 2010, Kosho et al., 2010). 
 
Skeletal dysplasias 
 
Skeletal dysplasias can also be associated with AMC (Hall et al., 1982a). Examples are the 
TRPV4-associated of disorders which are all characterized by brachydactyly, short stature 
with progressive spinal deformity and involvement of the long bones and pelvis and a 
recognisable radiological bone patten. Spondyloepiphyseal dysplasia is at the milder end of 
the spectrum with more severe phenotypic features seen in metatropic dysplasia. 
Arthrogryposis multiplex congenita-like contractures may be present in individuals with 
severe metatropic dysplasia secondary to the accompanying peripheral neuropathy. This 
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condition may be prenatally or perinatally lethal because of accommpanying extremely 
narrow chest and hypoplastic lungs (Unger et al., 2011).  
 
Metabolic Disorders  
Glycogen storage disease type VII (phosphofructokinase deficiency) can occasionally be 
identified as the cause of fetal akinesia and multiple joint contractures (Moerman et al., 1995). 
Perinatally, glycogen storage disease type IV can present with a cervical cystic hygroma, fetal 
hydrops, fetal akinesia. The patient may have a cardiomyopathy at birth, phenotypic features 
of lethal multiple pterygium syndrome and die in the neonatal period (Nolte et al., 2008, 
Akman et al., 2007). It is due to autosomal recessive mutations in glycogen branching enzyme 
1 (GBE1), (Ravenscroft et al., 2013). 
 
In contrast the joint contractures seen in the mucopolysaccharidoses are not usually present at 
birth and are progressive. Stiffness and contractures preferentially affect the phalangeal joints 
of the hand resulting in a claw hand deformity however other joints can also be involved 
including the hips, knees ankles and spine (Aldenhoven et al., 2009). 
 
Other fetal disorders  
 
Factors in the fetus that modify the in utero environment can cause arthrogryposis. The 
presence of amniotic fluid protects the developing baby from compression and facilitates free 
fetal movement. Oligohydramnios due to fetal kidney disorders such as kidney agenesis result 
in reduced fetal movements, joint contractures, pulmonary hypolasia and other features of in 
utero compression such as micrognathia and intrauterine growth retardation (Potter’s 
syndrome). Other causes of olighydramnios including leakage of amniotic fluid due cervical 
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insufficiency can result in similar features in the fetus (Vuopala et al., 1994, Wynne-Davies 
and Lloyd-Roberts, 1976).  
 
Arthrogryposis can be due to constitutional factors or specific genetic syndromes in the fetus. 
Chromosomal syndromes such as trisomy 18 (Edward syndrome) can be associated with joint 
contractures in the context of other malformations (Reed et al., 1985). Partial duplications of 
chromosome 1q have been seen in babies with absent fetal movements, fetal hydrops, finger 
contractures and the Pierre-Robin sequence, suggesting there may be dosage sensitive genes 
in this region (Aboura et al., 2002). Germline chromosome imbalances may be detected on 
blood samples and somatic mosaicism is more usually detected on cultured fibroblasts. 
 
 
 
 
Figure 4: Causes of Arthrogryposis 
(Adapted from Arthrogryposis: A Text Atlas, edited by Staheli, Hall, Jaffe, Paholke, Cambridge 
University Press, 1998). 
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1.4.2 Classification of arthrogryposis 
 
Arthrogryposis can be classified according to the pattern of joint involvement. AMC usually 
has proximal as well as distal joint involvement whereas there are predominantly distal joint 
contractures in the distal arthrogryposis syndromes. Additional features such as 
ophthalmoplegia and cleft palate in the affected members of the family may help in 
determining the phenotypic subtype. Arthogryposis is a component of many genetic 
syndromes including the multiple pterygium syndomes.  
 
1.4.2.1 Distal arthrogryposis  
 
This group of conditions is characterised by distal joint involvement most frequently finger 
contractures and talipes. In the upper limb there may be ulna deviation of the wrist, overriding 
digits, camptodactyly or decreased ability to straighten the fingers with wrist extension 
(pseudocamptodactyly). The ventral surfaces of the palms and fingers may appear smooth 
with faint or absent flexion creases due to lack of movement of the underlying joints. 
Additional features such as a cleft palate, an ophthalmoplegia or the puckered mouth 
characteristic of Freeman Sheldon syndrome may be used to identify specific clinical 
phenotypes with a different molecular basis. The classification of distal athrogryposis has 
been reviewed in the paper by (Bamshad et al., 2009). The distal arthrogryposes are usually 
inherited in an autosomal dominant pattern of inheritance with inter as well as intrafamilial 
variability in the range and severity of the phenotypic features present. Although one or other 
parent and other relatives may be similarly affected, distal arthrogryposis may be due to an 
apparently de novo condition in the family.   
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The genetic basis of all the subtypes of distal arthrogryposis is not currently fully understood 
however mutations in the troponin-tropomyosin-myosin complex of the muscle sarcomere 
have been identified in this group of conditions (see Figure 5). 
 
 
Figure 5: Diagram of the muscle sarcomere. 
Distal arthogryposis is caused by mutations in genes that encode the sarcomeric proteins: TNNI2 
(Troponin I), TNNT3 (Troponin T) and MYH3 (embryonic myosin).  
(Adapted from Toydemir et al., 2006). 
 
 
DA1 is characterised by camptodactyly of the fingers and talipes. The severity of the joint 
involvement is very variable. Other proximal joints such as the shoulders and hips are less 
frequently affected. It is an autosomal dominant condition due to heterozygous mutations in 
TPM2 (encoding tropomyosin 2).  
 
This pattern of joint contractures is also seen in Freeman Sheldon syndrome. This condition is 
associated with the characteristic “whistling face” because of the very small oral opening and 
puckered lips. Heterozygous mutations in MYH3 are identified in 90% of affected patients 
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(Sung et al., 2003a). Sheldon Hall syndrome (SHS) is characterised by distal joint 
contractures, downslanting palpebral fissures, prominent nasolabial folds and a small mouth.  
Mutations in MYH3 are also a frequent cause of SHS, however mutations in TNN12 (encoding 
troponin I), TNNT3 (encoding troponin T) and TPM2 can also cause this condition (Sung et 
al., 2003b, Sung et al., 2003a).  
 
DA5 is associated with distal arthrogryposis and ophthalmoplegia. This may be a genetically 
heterogeneous group of conditions as mutations in MYH2 and MYH13 have only reported in 
single families to date (Bamshad et al., 2009). 
 
 
1.4.2.2 Syndromes associated with arthrogryposis 
 
Arthrogryposis or multiple joint contractures can be associated with other features as part of a 
genetic syndrome. The following examples are single gene disorders associated with severe 
fetal akinesia and multisystem involvement.  
 
Arthrogryposis-Renal dysfunction-Cholestasis (ARC) syndrome 
 
ARC is an autosomal recessive condition due to mutations in the VPS33B and VIPAR genes 
(Gissen et al., 2004, Cullinane et al., 2010). It is multisystem disorder with features of 
neurogenic arthrogryposis multiplex congenita, renal tubular dysfunction and neonatal 
cholestasis. Currently there is no specific treatment for this condition and despite supportive 
care, most patients die in the first year of live. Liver cirrhosis and severe developmental delay 
are present in those with longer survival. 
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Fowler syndrome 
 
This is an autosomal recessive syndrome due to mutations in the FLVCR2 gene (Meyer et al., 
2010). The typical features of this condition are a proliferative vasculopathy and 
hydranencephaly–hydrocephaly. As well as joint contractures, webbing or pterygia across the 
joints indicating the presence of severe fetal akinesia has been noted in this condition. It has 
been recommended that this condition is considered in the differential diagnosis of the Lethal 
Multiple Pterygium syndromes (Williams et al., 2010).  
 
Multiple Pterygium syndromes 
 
In addition to arthrogryposis and pterygia or webbing across the joints, individuals affected 
with the Multiple Pterygium syndromes may have a variety of congenital abnormalities and a 
characteristic facial appearance. The focus of this project was the non lethal Escobar variant 
Multiple Pterygium syndromes (EVMPS) and the lethal Multiple Pterygium syndromes 
(LMPS). This group of conditions is discussed in more detail in the next section.  
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1.5 Multiple pterygium syndromes (MPS)  
 
The multiple pterygium syndromes (MPS) are a phenotypically and genetically  
heterogeneous group of disorders. They are characterised by arthrogryposis (joint 
contractures), pterygia (webbing across joints) and a variety of congenital developmental 
abnormalities, see figures 4 (i), (ii) and (iii). 
   
(i)
                
(ii) 
 (iii)
 
Figure 6: (i), (ii) and (iii). Features in a patient with MPS-Escobar variant.  
(Taken from Morgan et al., 2006).   
 
(i) Pterygium in the neck  
(ii) Arthrogryposis (joint contractures) of the fingers 
(iii) Elbow contracture and associated pterygium 
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Pterygium is a Greek word meaning “wing”. The MPS are characterised by multiple pterygia 
or webs across joint. Pterygia may be present in the neck, the axillae, the antecubital and 
popliteal fossae and intercrural region (Escobar et al., 1978, Gillin and Pryse-Davis, 1976, 
Stoll et al., 1980). The number and type of pterygia identified may be very variable between 
patients with MPS and within families affected with this condition (Hall et al., 1982b). 
Pterygia are believed to result from immobility in early life and it has also been suggested that 
early fetal oedema causes cutaneous folds in the joint regions (Van Regemorter et al., 1984). 
An alternative explanation for the formation of pterygia is that a genetically determined insult 
results in delayed development in the connection between muscle and lymphatic vessels. 
Obstruction to the drainage of fluid from the internal jugular vein into the jugular lymphatic 
vessels results in oedema. Pterygia are left with the resolution of the excess subcutaneous 
fluid as the link between the venous an lymphatic systems matures (Isaacson et al., 1984). 
Although pterygia may be observed before or at the time of birth, they may only become 
apparent or more obvious with time, suggesting that progression in the formation of the 
pterygia has occurred (Thompson et al., 1987, Ramer, 1991).  
 
Releasing the webbing across the affected joints does not usually increase the range of joint 
movement, as this is determined by the condition of the underlying joint. In addition, the 
muscle development around the affected joint is also abnormal. Older patients may be 
concerned about the cosmetic appearance of the ptergyia however care must be taken when 
considering surgical options as ptergia may contain the neurovascular bundle for that limb.  
 
 
Multiple congenital anomalies such as cleft palate, cryptorchidism, intestinal malrotation, 
congenital heart anomalies and cardiac hypoplasia, diaphragmatic hernia, genito-urinary 
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abnormalities, obstructive uropathy, microcephaly and cerebellar and pontine hypoplasia have 
all been described in patients with this condition. Respiratory impairment may be caused by a 
small chest size and spinal deformity. Multiple joint contractures and rocker bottom feet with 
a vertical talus are frequent in this disorder. In addition, an expressionless face, with facial 
dysmorphism including ptosis of the eyelids, down slanting eyes, a small mouth, cleft palate 
and micrognathia may be present. However, patients with MPS usually have a normal 
intellect (Thompson et al., 1987, Fryns et al., 1988, Hall et al., 1982b).  
 
The MPSs can be divided in to the milder Escobar variant (EVMPS, 265000), Figures 5 (i) 
and (ii), and the perinatally lethal MPS (LMPS, MIM 253290) (Hall et al., 1982b). Features of 
EVMPS include multiple pterygia, facial dysmorphism with downslanting palpebral fissures 
and bilateral ptosis, short stature and vertebra fusion, and other internal anomalies (Escobar et 
al., 1978, Rajab et al., 2005).  
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 (i) 
 (ii) 
Figure 7: (i) and (ii). Child with EVMPS variant MPS. 
(Taken from Morgan et al., 2006). 
 
(i) typical facies with downslanting palpebral fissures, bilateral ptosis and neck pterygia 
(ii) arthrogryposis of knees and rocker bottom feet 
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LMPS is characterised by features of the fetal akinesia deformation sequence (FADS) 
including severe flexion contractures or arthrogryposis, multiple pterygia, micrognathia, cleft 
palate, lethal pulmonary hypoplasia and intrauterine growth retardation. Extensive 
subcutaneous oedema causing fetal hydrops with cystic hygroma and lung hypoplasia may be 
detected on ultrasonography in pregnancy, Figure 8.  
          
Figure 8: 13 week old LMPS fetus with a pterygium across an elbow contracture. 
(Taken from Morgan et al., 2006). 
 
The identification of mutations in the fetal acetylchloline receptor (AChR) subunit gene 
(CHRNG) in a proportion of patients indicated an underlying mechanism for the fetal akinesia 
at least in this subset of the patient group (Morgan et al., 2006), as AChRs are essential 
neurotransmitter receptors at the neuromuscular junction. 
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1.5.1 The neuromuscular junction (NMJ) 
 
The NMJ is comprised of three highly specialised cells, the motor neurone, the muscle fibre 
and the Schwann cell. The motor nerve is adapted for neurotransmitter release by having a 
large number of ACh containing vesicles. The postsynaptic membrane has a high 
concentration of AChRs located on the crests and part-way down the sides of the post-
synaptic membrane folds to enable a rapid reliable response to neurotransmitter release 
(Covault and Sanes, 1986, Flucher and Daniels, 1989). The processes of the Schwann cell 
provide an insulating cap and possibly trophic factors for the nerve terminal. 
 
At the neuromuscular junction, motor neurone activity causes the release of ACh from 
vesicles in the presynaptic membrane (Figure 9). This results in end plate potentials which 
generate an action potential. Opening of voltage gated sodium channels causes a rapid sodium 
ion current inwards. Repolarisation of the membrane occurs by inactivation of the sodium ion 
and potassium ion channels. The signal is transmitted along the surface membrane to the 
deeper parts of the muscle fibre. The voltage gated pentameric calcium channel or 
dihydropyridine receptor senses membrane depolarisation, alters its conformation and 
activates the ryanodine receptor which releases calcium ions from the sarcoplasmic reticulum. 
Calcium ions bind to troponin and activate the contractile machinery resulting in muscle 
contraction. This mechanism is impaired by abnormalities in any of the critical components of 
this process. 
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Figure 9: Diagram of the neuromuscular junction. 
On activation of the motor nerve, vesicles containing the chemical acetylcholine (ACh) fuse with the 
presynaptic membrane. ACh is released from these vesicles into the synapse. The ACh binds with the 
AChRs on the postsynaptic membrane of the muscle fibre. This causes a cascade of reactions culminating 
in muscle contraction.  
 
 
1.5.2 Acetylcholine receptors (AChR) 
 
These neurotransmitter receptors are found in both neuronal and non neuronal tissues 
throughout the body and are activated by acetylcholine (ACh). The two types of AChR are 
subdivided into muscle (muscarinic) or neuronal (nicotinic) AChRs, depending on their site of 
expression and the local muscle innervation.  Muscarinic receptors can be activated by 
Amanita mushroom muscarine toxin and are inhibited by the toxin atropine from the Atropa 
belladonna nightshade family. Structurally they have seven transmembrane domains and 
function as second messengers in G-protein coupled reactions. Activation of these receptors is 
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relatively slow and results in a direct effect on cellular homeostasis. They have a particular 
role in postganglionic parasympathetic nervous system reactions (Hulme et al., 1990).  
 
Nicotinic AChR are activated by nicotine. The nicotinic AChR is a pentameric 
transmembrane protein comprised of four different subunits with a central pore (Noda et al., 
1983, Shibahara et al., 1985). These receptors have ion channels which can be activated 
within microseconds and thus have the ability to provide a rapid reponse. Binding of an ACh 
agonist to these receptors causes a change in the flow of ions and thus a cellular response. 
Nicotinic AChRs are comprised of subunits with homologous structural units, a large terminal 
extracellular NH2 domain, three transmembrane domains, a cytoplasmic loop of a variable 
amino acid composition and size and a fourth transmembrane domain with a short variable 
and a terminal extracellular COOH sequence. In common with all ligand gated ionic channels, 
there are two cysteine residues separated by 13 intervening amino acids to enable an agonist 
to bind. The various domains are folded to optimise their specific cellular functional role. In 
particular, configuration of the subunits results in a wide channel at the mouth of the receptor 
constricted by the encircling extracellular domains to enable closure of the gated receptor. 
 
AChRs subunits can be very diverse and the receptor pentamers can be composed of various 
subunits enabling highly specialised tissue specific signalling functions. Interestingly, the 
nicotinic AChRs are conserved throughout the various life forms because of their role in 
muscle contraction, and thus may be a target for attack. Hence the role of nicotine from the 
tobacco plant as a pesticide in farming and horticulture.  
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In skeletal muscle the nicotinic AChR mediates neurotransmission across the neuromuscular 
synapse. Release of the agonist ACh from vesicles on the presynaptic membrane and binding 
with AChRs on the postsynaptic membrane causes opening of a selective cation channel. This 
results in an ionic current that depolarises the membrane and leads to muscle contraction. 
Clustering of the AChRs on the postsynaptic membrane is critical to enable a significantly 
large synaptic potential to be achieved to initiate an action potential in a muscle fibre. 
Acetylcholinesterase inhibitors can be utilized to potentiate the effects of ACh in disease, by 
increasing the quantity and duration of the agonist in the synapse.  
 
The nicotinic AChR exists in an adult forms and a fetal form. The embryonic AChR 
predominates in fetal and denervated muscle and consists of two alpha and one beta, one 
gamma and a delta subunit (α2βδ), see Figure 10. The adult form is present in innervated 
adult muscle (Xu and Salpeter, 1997). In adult AChRs the gamma subunit is replaced by an 
epsilon subunit (α2βεδ). In humans the switch from  to  and the transition from a fetal to 
adult AChR occurs during fetal life and is complete by 31 weeks of gestation, whereas in 
rodents the switch occurs postnatally (Hesselmans et al., 1993, Bouzat et al., 1994, Kues et 
al., 1995, Yumoto et al., 2005). This switch is believed to be induced by the nerve derived 
chemical ARIA (acetylcholine receptor-inducing activity), thus there may be differential 
expression of ARIA when promoters of the γ and ϵ subunit genes are activated (Missias et al., 
1996).  
 
Embryonic and adult forms exist for many proteins in the body to support the different 
functional requirements in pre and postnatal life. The embryonal and adult AChR have 
differing conductance and gating suggesting the  to  subunit switch causes functional 
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alterations in the AChR during muscle maturation (Mishina et al., 1986). The embryonic 
AChR has long opening times allowing the release of acetylcholine to generate spontaneous 
muscle action potentials. This is in contrast to the adult receptor, which has shorter mean 
channel opening times and consequently short-lived mini end plate currents. Experimental 
work has shown that only embryonic miniature end plate currents last long enough to trigger 
contraction in fetal muscle. As fetal muscle must be active for postsynaptic membrane 
specialisation and muscle differentiation, it has been suggested that the characteristics of the 
embryonic AChR are essential for the spontaneous contractile activity necessary for normal 
development of the neuromuscular motor terminus in utero (Jaramillo et al., 1988, Bouzat et 
al., 1994). In -subunit deficient mice pre- and post synapses are abnormal and there is 
absence of spontaneous action potentials from the minature end plate potentials reinforcing 
the critical importance of  containing AChRs in neuromuscular development (Takahashi and 
Alford, 2002). Further study has highlighted the role of the fetal AChR in ensuring an orderly 
innervation pattern in skeletal muscle. The functional end plate properties associated with 
adult AChRs consisted of shorter mean opening times, a larger conductance and increase in 
calcium ion flux, essential to preserve a functional neuromuscular synapse (Koenen et al., 
2005). Mice deficient in -AChR subunits have persistence of the -AChRs at the end plates 
at reduced density with resulting impaired neuromuscular transmission, progressive muscle 
weakness and premature death illustrating the need for -AChR postnatally (Witzemann et al., 
1996).  
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Figure 10: The subunits of the embryonic AChR. 
(Adapted from Molecular cell biology, sixth edition, 2008. W.H. Freeman and company). 
 
 
1.5.3 CHRNG 
 
CHRNG encodes the gamma subunit of the embryonic AChR. The CHRNG gene 
is located at chromosome 2q33-q34. It is composed of 1545 base pairs and has 514 amino 
acid residues arranged in 12 coding exons. Structurally, the gamma subunit contains a large 
extracellular N terminus through which it binds acetylcholine, four transmembrane domains 
numbered M1 to M4, a large cytoplasmic domain between the M3 and M4 domains and a 
short extracellular C terminus (Shen et al., 2005), Figure 11. It is expressed in the post- 
 
β 
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synaptic membrane of the face, limbs, paravertebral, intercostals, diaphragmatic and neck 
muscles in fetal life.  
 
 
Figure 11: Diagram of CHRNG.  
(Adapted from Morgan et al., 2006). 
 
 
The identification of CHRNG mutations in MPS patients suggested that pterygia resulted from 
early onset fetal akinesia. Although the embryonal AChR has a key role in normal prenatal 
muscle development, the  subunit is not required postnatally thus Escobar variant MPS 
patients do not demonstrate marked progressive muscle weakness (Hoffmann et al., 2006). 
There remains however uncertainty about the mechanism and cause of the other variable 
associated developmental anomalies.  
NH2 
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Following detection of CHRNG mutations in MPS I undertook a genotype-phenotype study to 
investigate the clinical features that may predict the presence of a CHRNG mutation and 
whether the CHRNG mutation spectrum differed between LMPS and EVMPS kindreds. 
CHRNG mutation analysis was performed in 100 families with a clinical diagnosis of 
MPS/FADS (see Chapter 3). Clinical data about the cohort was collected using a clinical 
features questionnaire. This work has also been included in the publication genotype-
phenotype correlations in the multiple pterygium syndromes (Vogt et al., 2012). 
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1.5.4 Gene mapping in the Multiple Pterygium Syndromes 
The multiple pterygium syndromes are most commonly, though not exclusively, autosomal 
recessively inherited. Gene identification in autosomal recessive disorders has been difficult, 
due to the rarity of individual conditions and family size, as families with more than two 
affected siblings within a sibship are infrequent. When considering gene discovery in MPS, 
techniques such as autozygosity mapping in autosomal recessive families, candidate gene 
analysis and second generation sequencing for novel genes have been utilized. 
 
1.5.4.1 Autosomal Recessive Diseases 
 
Autosomal recessively inherited diseases are responsible for a wide spectrum of 
developmental, metabolic and medical problems. Many of these conditions manifest in 
childhood and cause a significant excess morbidity and mortality in consanguineous families 
(Bundey and Alam, 1993). In autosomal recessive conditions the affected individual has 
mutations on both copies of a specific gene located on one of the autosomes. The parents of a 
person affected with an autosomal condition each have one copy of the mutated gene and are 
thus carriers of the condition. For a couple that are carriers of an autosomal recessive 
condition there is a 1 in 4 or 25% chance of having an affected child in each pregnancy. Males 
and females have an equal chance of being affected (Strachan and Read, 1999). Although 
autosomal recessive conditions are rare, the frequency of particular conditions may be 
increased in populations with a high carrier frequency or in communities that practice 
consanguineous marriages, with the greatest effect the more closely the parents are related 
(Smith, 1974). Identification of disease causing genes enables diagnostic, prenatal and carrier 
testing to be offered to affected families. In addition, the study of the disease causing genes 
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helps to improve the understanding of gene function, the pathogenesis of disease and the 
potential therapeutic targets for treatment.   
 
1.5.4.2 Autozygosity Mapping 
 
In 1987 a powerful approach to identifying disease genes from the linkage information 
yielded from the affected children born to consanguineous partnerships was described (Lander 
and Botstein, 1987). The technique of autozygosity mapping utilizes the fact that the 
consanguineous parents of a child affected with a rare autosomal recessive disease are likely 
to be autozygous for markers linked to the disease locus. The disease causing mutation and 
the adjacent chromosomal segments may be expected to be homozygous or identical by 
descent in the affected individuals (Lynex et al., 2004). First cousin parents would be 
expected to share 1/4 of their genes and their offspring autozygous at 1/16 of all loci because 
of their common ancestry. The offspring of second cousin parents would be estimated to be 
homozygous for 1/64 of their genome. The offspring of double-first cousins would be 
expected to be homozygous for 1/8 of their genome.  However, greater homozygosity may be 
observed in populations with a long history of prolonged consanguinity and consequently a 
higher background level of homozygosity. In these circumstances it has been calculated that 
that for the offspring of first cousin parents on average 11% (range 5%–20%) of their 
genomes are homozygous (Woods et al., 2006).  
 
These homozygous segments can be searched as a method for localising disease genes. It has 
previously been shown that most pathogenic mutations are identified in regions of 
autozygosity greater than 4 cM (Woods et al., 2006). Autozygosity mapping has been  
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used very effectively to map rare recessive genes, particularly in areas where consanguineous 
marriages are usual or families originate from isolated populations (Houwen et al., 1994). The 
power of this technique in comparison with the analysis of small nuclear families has been 
calculated mathematically. However, it is important to consider genetic heterogeneity when 
pooling the linkage information from different complex consanguineous families (Mueller 
and Bishop, 1993).  
 
1.5.4.3 Candidate Gene Analysis 
 
Evaluation of candidate genes is a method used to search for susceptibility genes in 
population based association studies. In this approach, markers such as microsatellites or 
SNPs (single nucleotide polymorphisms) are used to map Quantitative trait loci (QTLs), 
stretches of DNA containing or linked to the genes associated with that disease phenotype by 
comparing the patient population with healthy controls. This method may be successful if 
there is a disease causing genetic variant identified in the disease population that is not present 
in the control group. This technique may be more efficient when the pathogenesis of the 
condition is understood either in human or model organisms. Likely candidate genes can be 
selected and screened using Sanger sequencing for causative mutations. Although this 
strategy may be successful, it is relatively time consuming and expensive. In addition, new 
mechanisms of disease may not be identified with this method. The efficacy of candidate gene 
analysis depends on factors such as accurate clinical phenotyping, the size of the population to 
be studied and the number of available markers. 
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1.5.4.4 SNP arrays 
 
SNP arrays utilize DNA sequence variation to study the variations throughout the whole 
genome. Humans carry the same base residue on both chromosome homologs at the majority 
of genomic sites. However in the remainder, single nucleotide polymorphisms (SNPs), two 
distinct alleles or nucleotides, are present in a proportion of the population. There are 
estimated to be approximately 10 million SNPs in the human genome (Kruglyak and 
Nickerson, 2001). Each SNP on the array is interrogated with different probes. These are 
labelled as SNP A and B. For an individual, their genotype at each SNP site is usually either 
AA, AB or BB. About one million SNPs are analysed in one assay. The genotyping accuracy 
is estimated to be greater than 99%. 
The arrays contain hundreds of thousands of nucleotide probe sequences. Each probe is 
designed to bind a target DNA sequence, as nucleotide bases bind their complementary 
sequences. The signal intensity measured depends on the quantity of target DNA in the 
sample and the affinity between the target DNA and the probe. This method enables detection 
of stretches of homozygosity due to inheritance of haplotypes identical by descent.   
 
 
1.5.4.5 Second Generation Sequencing 
 
The development of high throughput sequencing technologies allows extensive mutation 
screening to be undertaken at increasingly lower costs. Massively parallel sequencing of large 
numbers of DNA amplicons has the advantage of accelerating detection of novel genes in the 
pathogenesis of disease, providing information about normal development and disease 
mechanisms and improving health care with the promise of personalised medicine. Whole 
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exome sequencing (WES) uses next generation sequencing technology to identify sequence 
variants in all the known coding exons. The human genome contains approximately 3x10
9
 
coding and non-coding bases arranged in 180,000 exons, comprising about 1% or 30 Mb of 
the total human genome. WES covers over 95% of these exons, which has been estimated to 
contain about 85% of the mutations causing single gene disorders and single nucleotide 
polymorphisms (SNPs) predisposing to common diseases and cancer. Exome sequencing is 
therefore considered to be more efficient than genome sequencing as the majority of genetic 
variants in Mendelian disorders disrupt protein coding sequences. In addition, a large number 
of rare non synonymous substitutions are predicted to be deleterious and there is a high 
functional variation in splice site sequences. It has a higher coverage and a lower cost. These 
techniques can be used together to improve the detection rate of disease causing genes. For 
example homozygosity mapping using SNP arrays for genome wide linkage analysis in 
consanguineous families has successfully been used to target the exome sequencing region for 
interrogation and gene identification (Bolze et al., 2010). A limitation of this technique is the 
inability to detect variation in non-coding genomic DNA and epigenetic phenomenon which 
may cause or modify the clinical phenotype, and to reliably detect exon deletions and 
duplications. Due to the large number of human SNPs various strategies have been utilized to 
filter out variants unlikely to be disease causing using public databases such as dbSNP and 
HapMap. Inhouse and ethnicity-specific data collections can also be a useful adjunct to assist 
in identifying plausible variants.  Categorisation to indicate the degree of pathogeneicity that 
may be attributed to each variant may help in current and future interpretation of genomic 
variation.  
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1.5.4.6 Identification of disease genes and bioinformatics 
 
Following the identification of a suspected disease causing gene mutation, the variant is 
further evaluated for features consistent with pathogenicity. Supportive features include 
appropriate segregation within families and its absence (or very low frequency) in ethnically 
matched controls. The variant should be in a credible candidate gene. Properties of the variant 
that need to be assessed include the predicted effect on protein structure and function and the 
evolutionary conservation. Disease causing genes and the sequence variants are incorporated 
into several genetics databases. Examples include Ensembl, The Human Gene Mutation 
Database and OMIM (Online Mendelian Inheritance in Man). The information included on 
these gene resources enables further disease associated study. The Leiden Open Variation 
Database (LOVD) also includes patient specific clinical information with the mutation thus 
enabling genotype phenotype correlations to be made. With the advent of exome and genomic 
technologies, sophisticated sifting and analyzing of data will be essential for interpretation 
and clinical use. 
 
1.5.4 Aims and objectives of the MPS/FADS study 
 
The main aim of this project was to advance the identification and understanding of the 
molecular and biological basis and the phenotypic features of the MPS/FADS for families and 
their clinicians.  
Information about the genetic basis of a condition is important for the management of families 
with autosomal recessive conditions. In addition to providing parents with information about 
the cause of the condition and the chance of recurrence, the possibility of early prenatal or 
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pre-implantation diagnosis may be made available for carrier couples at risk of having an 
affected child and carrier testing of relatives can be offered. 
The objectives were thus to: 
 Establish a large patient resource of MPS (Escobar-variant and perinatally lethal) 
families.  
 
 CHRNG mutation analysis and a genotype phenotype correlation study  
 
 Produce an online CHRNG mutations database resource detailing the type and position 
of the CHRNG sequence variants detected  
 
 Identification of new MPS/FADS candidate genes 
 
 Develop a practical molecular pathway to investigate MPS/FADS families 
 
 Finally, the development of new technologies and how this can be incorporated into 
the search for and identification of further genes causing MPS will be considered. 
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Chapter 2: Materials and Methods 
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2.1 CHRNG Genotype Phenotype Correlations Study 
2.1.1 Patients and Methods 
 
100 families with at least one individual with clinical features of EVMPS, LMPS or FADS 
were recruited to this study. Entry criteria specified EVMPS/LMPS or FADS of unknown 
cause and so the cohort was representative of this group of families but not of all cases of 
these disorders. Ethical approval and valid consent was obtained. DNA samples from the 
probands and, where possible, the parents were collected. Mutation analysis of all 12 coding 
exons of CHRNG was performed by direct sequencing. Homozygous CHRNG mutations 
c.320T>G (p.Val107Gly), c.136C>T (p.Arg46X), c.401_402delCT (p.Pro134Argfsx43), 
c.753_754delCT (p.Val253AlafsX44), c.459dupA (p.Val154SerfsX24) and the possible 
mutation IVS4-9T>C (c.351-9T>C) in 6 families (15 affected individuals) have been 
described previously, (Morgan et al., 2006).  A standardised questionnaire was used to gather 
phenotypic information including details of the family history, ethnicity, perinatal and 
postnatal history. The results of the relevant investigations, including brain scans and muscle 
biopsy results were recorded where available. Genotype-phenotype correlations were 
evaluated by subdividing the cohort into nonlethal and lethal patients and CHRNG mutation 
positive/negative groups. In families with multiple affected siblings, an analysis was 
undertaken to estimate the likelihood of a further affected pregnancy with a similar 
phenotype. 
 
Statistics: Analysis was undertaken using Fisher’s exact test.  Statistical significance was 
taken at the 5% level. 
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2.1.1.1 Multiple Pterygium Syndrome Questionnaire 
 
Name:       Male   Female  
Date of Birth:     Ethnic origin: 
Hospital number:   
 
Major features: fetal akinesia +/ multiple pterygia  please delete as appropriate 
 
Clinical History 
Pregnancy:          
Duration 
       *First detected in gestational week  
      Yes  No Unknown  Details (e.g. onset) 
Intrauterine growth retardation   __   
Polyhydramnios     __   
Oligohydramnios     __   
Cystic hygroma, oedema, hydrops fetalis  __   
Reduced fetal movements    __   
Joint contractures     __   
Other abnormalities noted on USS   __   
Other abnormalities     __   
 
Neonatal period <1 month    Bwt__  Length__ Head 
circumference__    
 
      Yes  No Unknown Details 
Respiratory problems        
Cardiac problems        
Other          
 
Clinical Features 
Growth      Weight__  Height__ Head 
circumference__            
 
      Yes  No Unknown 
Craniofacial anomalies         
Expressionless face        
Facial haemangioma        
Eyes: downsloping palpebral fissures     
            ptosis         
            epicanthic folds       
            hypertelorism        
Nose: depressed nasal bridge      
Oral: cleft palate        
  high arched palate       
            small mouth        
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             micrognathia                
Ears:  low set                 
             malformed                
 
     Yes No  Mild     Moderate Severe 
Pterygia: neck                      
                        axillae                      
                        elbows                      
                        groins                      
                        knees                      
                        other      Details: 
 
 
     Yes No 
Consent for photography    
 
 
Flexion contractures:  limitation of movement  degrees of movement 
   
     Yes No 
Shoulders       _____ 
Elbows       _____ 
Wrists        _____ 
Fingers       _____ 
Hips        _____ 
Knees        _____ 
Ankles        _____ 
Other        Details:  
 
 
Muscle weakness     
Muscle fatigability     
 
Hand abnormalities       Details:  
Foot abnormalities:      Details:  
 
Arachnodactyly     
 
Bony anomalies      
Vertebral fusion     
Scoliosis      
Ribs       
Other       
 
 
Cryptorchidism     
Other genital anomalies    
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Hearing loss      
Soft vocalization /nasal speech   
 
Developmental delay     
 
Other features       Details:  
 
Family History (please enclose family tree) 
 
     Yes No  Male Female 
Affected sibling        
Other affected relatives        Details:
  
   relationship to proband   
         
     Yes No Unknown  
Previous stillbirths /       Gestation: 
perinatal deaths       Details: 
 
     Yes No Unknown 
Consanguinity       
 
 
Laboratory results    Yes No N/A Date Details 
Post mortem       
Nerve studies       
EMG        
Biopsy        
Maternal AChR Abs      
Ratio anti-fetal /anti-adult AChR    
Chromosomes        
other        
 
 
 
  
   
  
Thank you for your help.  
 
Form completed by ………….    Date …………… 
 
 
Contact details:   
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2.2 Candidate Gene Analysis of CHRNA1, CHRNB1, CHRND, 
RAPSN and DOK7 
2.2.1 DNA samples 
 
Patient DNA samples were obtained from a number of sources, including clinicians both 
within Europe and around the world. All families gave informed consent and the study was 
approved by the South Birmingham Research Ethics Committee. Where possible, completion 
of the clinical questionnaires was requested.  
2.2.2 Primers 
 
CHRNG   
Exon1-2F  CATCTCTCTCTGCCCCAGAC 
Exon1-2R  ATGCTATCCCCAGCAGGTC 
Exon3-4F  GTGGGGACTGGCACTGAAG 
Exon3-4R  CAGAGTGCCTTGTTCTGCTG 
Exon5F CCTATCCACATGGGGCAC 
Exon5R CAGAGCCAAGGCCAGAAG 
Exon6F ATGCAGTCGTGGCAGGTC 
Exon6R TCCAGCCTTGACCACAGC 
Exon7F GGGATCTGCCTAGCTCACG 
Exon7R TCTGTTCCCCAGGCAGG 
Exon8-9F  GCTACTTCTGGGGTAAGGGG 
Exon8-9R  AGAGGGAGGCGTAGGGG 
Exon10F CAACCTCTGGCTTCTGCTC 
Exon10R ACTCATCTGCTGTGCCTGG 
Exon11F GAGAGGCCATCTTCTCTGCC 
Exon11R CTCTATCACGGTTCCAAGCC 
Exon12F CCCAAGGATGAGAACAGGAC 
Exon12R AAGACTCAGTGTGACCCACG 
 
 
CHRNA1   
Exon1F AGTGCCAGTGAGAAGCACAG 
Exon1R AGCAAGACTTTGATTTGGGG 
Exon2-3F TCATGTGTTTGGAGGGTGG 
Exon2-3R GGGCCCAGGTTTAATTTCAG 
Exon4F ATGCACATCAGGGCTCTTG 
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Exon4R CTTTATTCCACCTGCCCC 
Exon5F AGCAGAATGGAAGGCTCATC 
Exon5R AAGGAAAAGTTGGAGACCCG 
Exon6F CTGATTACAAAACGCTGCCC 
Exon6R ATAGCAGCACGAGACCCATC 
Exon7F TATAAATGGTGGGGTGGGAG 
Exon7R GGGGAGGCCTGTAGATGTG 
Exon8F TGACTTACCCCAAATCACATTG 
Exon8R CAGACTCACCACCTGTGCTC 
Exon9F AGCACAAACGTTGTGAGTCC 
Exon9R ATCTTCCTCTCCTGCCCTTC 
 
CHRND   
Exon1-2F CACCCTCATTCCACAGCC 
Exon1-2R CCTGGTACTGGAAAGCCATC 
Exon3F GAGAGTGGGTGAATGTGTGC 
Exon3R CTTGATCTCCTGACCTCGTG 
Exon4-5F AGGAGCCTGGATGGCTG 
Exon4-5R AGGGTGCTTCAGTCACCTTC 
Exon6F CTTACCAGCCCTTCCCCAC 
Exon6R GACAGGGCCAGTGTGTCTG 
Exon7F AGCCCCTCATTCTGTCCC 
Exon7R GCTGGCTGTGCTCAGGTG 
Exon8-9F CAGCTGGACCCTCTAGGACC 
Exon8-9R GCCTCAGCCTCCTGAAATG 
Exon10-
11F CAGCCTGGTGACAGAATGAG 
Exon10-
11R TTGGTGTGTGCCTCTAAGGG 
Exon12F GGGCTTTGTGGCCTGAG 
Exon12R AGGAGTGGGTGTCATTAGGG 
 
 
CHRND   
Exon1-2F CACCCTCATTCCACAGCC 
Exon1-2R CCTGGTACTGGAAAGCCATC 
Exon3F GAGAGTGGGTGAATGTGTGC 
Exon3R CTTGATCTCCTGACCTCGTG 
Exon4-5F AGGAGCCTGGATGGCTG 
Exon4-5R AGGGTGCTTCAGTCACCTTC 
Exon6F CTTACCAGCCCTTCCCCAC 
Exon6R GACAGGGCCAGTGTGTCTG 
Exon7F AGCCCCTCATTCTGTCCC 
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Exon7R GCTGGCTGTGCTCAGGTG 
Exon8-9F CAGCTGGACCCTCTAGGACC 
Exon8-9R GCCTCAGCCTCCTGAAATG 
Exon10-
11F CAGCCTGGTGACAGAATGAG 
Exon10-
11R TTGGTGTGTGCCTCTAAGGG 
Exon12F GGGCTTTGTGGCCTGAG 
Exon12R AGGAGTGGGTGTCATTAGGG 
 
 
RAPSN   
Exon1F ATTCCTGCCCCATGAGTG 
Exon1R GGAGCCTGGGAGACATCC 
Exon2F TGGGGTCCAAGGCTCAG 
Exon2R GTAGTGCCACAGGGTGTGTG 
Exon3F ACTTGGGGCAGCCTCTG 
Exon3R AAGAAGGAAGCCCTGCTGTC 
Exon4-5F GGTCTGTTGAGGGGAGGG 
Exon4-5R TAACCTACTGGCCCCAAGTG 
Exon6F GTGCTTCCCTGTGAGCAAG 
Exon6R CTTCCCCAGACCCAAGTTC 
Exon7F GACAGGGAAGTGGCTGAGAC 
Exon7R TCTCTGACTCCTCTTTGGGG 
Exon8F CAGGCAAGGAAGGAAGAGAG 
Exon8R TGCAGTGGAGAAAGAGCAGG 
 
DOK7   
Exon1-2F CTGCGAGCTATTTTGAAAGTG 
Exon1-2R  CTCGGTAACCCGTGTCG 
Exon3F GGGTCTCTGCACTGTCACG 
Exon3R CTCCCACCTCTGCAGCC 
Exon4F TGATGTCCTCTCACCCTGC 
Exon4R CCGAAGCCAGCAGTTCTC 
Exon5F CTGTGTTCCTCCTCTTCAGG 
Exon5R CTAACTGGGGCTGACAAATC 
Exon6F ACTGAGTCAGGCTGGGC 
Exon6R ATGCCTCCTGAGCTCTCC 
Exon7_1F GAGACCAGAGAGTGCTGGC 
Exon7_1R  CTGCGTGGTGTGTCATAGTG 
Exon7_2F  CAGCCTCTCGTCCTACGC 
Exon7_2R  CACAGAACACAGAGCACCAG 
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DAG1   
exon2F GGTGTGCAGAGGGTGAGAAC 
exon2R CTTGAAAAGGAAAAGCCACC 
exon3_1F AAACCTGTCACACAATTCAGG 
exon3_1R GCACACTGTTCTGGTTCAGG 
exon3_2F CAGACTATTTGACATGTCGGC 
exon3_2R GGATACTCGTGGCTTCTTGG 
exon3_3F GATTCGCCCAACGATGAC 
exon3_3R GCCTGTGGACGTGGATCTC 
exon3_4F AGTTCAACAGCAACAGCCAG 
exon3_4R AGGTAGACATCATCCTCACTGC 
exon3_5F CGGCACCTACAGTTTATCCC 
exon3_5R CAACACCATGTCGTCTCCAG 
 
MUSK   
exon1F CTGTGGAGCCATTTTCCTTG 
exon1R AAAACCCAAGCCCACCATAC 
exon2F TTTGATTTCTCTTTCCTTTCA 
exon2R TGTATCAAAACATCTCATCTACTTCA 
exon3F TTCCTCATTAACAAGTCATCGG 
exon3R GTGAACCGAGATCATGCC 
exon4F TGCCTCAAATGATTCTCAAAAC 
exon4R CCAAATGAAATGCCATGCAG 
exon5F TTGGCAAATGTATCCTTGATAGAC 
exon5R TCACAGTAGACAGTGAGGCCC 
exon6F CACCCTAGCTTGACCATTTCC 
exon6R CCTGAAGTTCACCACCAATG 
exon7F TGCTTTTCCCTTCAAATCTACTG 
exon7R GGGAGATTTTCTCCAATGCTC 
exon8_9F TTTCTGAGACACAGATGTGAAAAC 
exon8_9R AAACTCCTTCTGTTGTGCAGATAG 
exon10F AACACAGAATTTAGGCTCTGCC 
exon10R GAAGCTTTAAGTTCACACCTTAGTTTC 
exon11F GCACTCACTCTCTCACAGAATATG 
exon11R ACACATGCATGAATCCAATTAC 
exon12F AATATATAACCAGGGAGAACCTGATAC 
exon12R TCCTCACGTCATACCAACTCC 
exon13F AAGTCTAAGTACAAAGATCTAACCTGC 
exon13R GCTAATAGTTTGGTAGCTTTTCAGAC 
exon14F AGCCTTTTACACAGGGGAGG 
exon14R AAAGCACGAACAAGGGGAG 
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exon15_1F GCTTTTGGAGTGCTCTTTCC 
exon15_1R AAATGGACTCTGGTGGCATC 
exon15_2F GTGAAAATTGCCGACTTTGG 
exon15_2R CCTCTGGTGTAGGATTCCCC 
 
 
2.2.3 Microsatellite markers  
(Human Genome Assembly Build 36) 
 
Marker Start position (bp) End position (bp) Approximate size Marshfield deCODE (cM) 
CHRNG           
D2S1363 226737850 226738038 164-204 227 229.1 
D2S396 230391872 230392111 230-244 232.9 252.5 
D2S427 231914508 231914752 243-263 236.7 238.2 
D2S2193 231945632 231945898 239-271 236.7 238.2 
D2S2344 233152938 233153148 193-221 238.3 239.3 
D2S206 233416066 233416307 123-151 240.8 240 
            
RAPSN           
D11S4109 47558064 47558236 155-185 58.4 63.8 
D11S1344 46123506 46123786 273-293 58.4 63.5 
            
DOK7           
D4S412 3417660   237-249 4.7 4.4 
D4S2935 6678952   104-120 14 14 
D4S2366 6602749   120-144 12.9 12.5 
 
 
2.2.3 PCR Amplification for Sequencing 
 
Standard conditions for PCR amplification were used. For each reaction 50-100 ng of 
genomic DNA, 1 x Taq polymerase buffer, 500 M dNTP’s, 5.0 pmol of forward and reverse 
primers and 1.5 U of ABgene Taq DNA polymerase were made up to 25 l with dH20. PCR 
conditions were: an initial denaturation of 95
o
C for 5 minutes, followed by 34 cycles of 45 
seconds denaturation at 95
o
C, 45 seconds annealing at 50-65
o
C (depending on the reaction) 
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and 45 seconds extension at 72
o
C. This was followed by a final extension at 72
o
C for 10 
minutes. The PCR products were cleaned up using ExoSAP purification.  
2.2.4 Sequencing of Candidate genes 
 
The purified PCR product was sequenced in both forward and reverse directions using the 
relevant primers. The 10µl sequencing reaction was set up with 1 l Big Dye Reaction Mix, 2 
l 5x Sequencing buffer, 3.5 l Purified PCR product, 2 l Forward or Reverse Primer (2 
pmol/l) and 1.5l Water. The cycling conditions were 96oC for 3 minutes followed by 30 
cycles of 96
o
C for 30 seconds, 50
 o
C for 15 seconds and 60
o
C for 4 minutes.  
 
Sequencing reactions were cleaned up to remove any unincorporated dye terminators prior to 
electrophoresis. 1 l of EDTA (250 mM) was added and mixed to each 10 l sequencing 
reaction before adding 30 l of absolute ethanol. This was incubated for 15 minutes at room 
temperature and then centrifuged for 20 minutes at 2000 rpm at 20°C. The supernatant was 
removed by briefly spinning the plate upside down to 400rpm. 90 l 70% ethanol was then 
added, mixed and the plate centrifuged at 2000 rpm for a further 10 minutes at room 
temperature. The supernatant was again discarded by inverting the plate and spinning to 400 
rpm. The pellet was then left to air dry. 
Sequencing reactions were resuspended in 10 l Hi-Di Formamide and denatured for 2 
minutes before snap chilling on ice. 
2.2.5 Microsatellite Marker studies 
 
PCR amplification was performed in 10 l reactions containing 20 ng of genomic DNA, 1 x 
Taq DNA polymerase buffer, 1.5 mM MgCl2, 0.5 U Taq Polymerase, 2 mM dNTP and 2.0 
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pmol each primer (forward fluorescently labelled and reverse). After an initial denaturation at 
95
o
C for 5 minutes, a standard PCR protocol was followed consisting of 28 cycles of 95
o
C for 
30s, annealing at 55
o
C for 30s and extension at 72
o
C for 30s, followed by a final extension 
step at 72
o
C for 5 minutes.  
67 
2.3 Mapping New Genes 
2.3.1 SNP arrays 
In consanguineous families with autosomal recessive conditions, the assumption is that the 
causative gene will be located in a region of homozygosity shared between the affected 
individuals in the family because of homozygosity by descent for the disease gene. A 10cM 
genome-wide linkage scan was carried out by Louise Tee using the Affymetrix 250K SNP 
chip in two affected siblings from the branch of the a family (II.3 and II.4) and a similarly 
affected cousin (II.5) from the b branch of the family, in order to identify common regions of 
homozygosity. In particular regions larger than four megabases were sought, as these are most 
likely to contain the pathogenic gene (Woods et al., 2006). Further analysis and fine mapping 
of the homozygous region was undertaken using microsatellite markers in the available 
parents and offspring for whom DNA was available.  
2.3.2 Microsatellite markers  
 
Marker Start position (bp) End position (bp) 
Approximate 
size Marshfield 
deCODE 
(cM) 
D3S1300 60484947 60485189 217-241 80.3 82.2 
D3S1481 60633630 60633711 104   82.58 
D3S1239 62034672 62035006 189-193 82.2 84.7 
D3S1312 62381446 62381761 215-225 82.2 85.1 
D3S3566 62517629 62517997 218-234 81.4 85.1 
D3S3698 63094791 63095178 270-278 84.9 86.4 
D3S1600 63294878 63295304 182-198 86 86 
D3S3644 64772879 64773050 164-176 91.2 89.3 
D3S1285 64914199 64914434 232-242 91.2 89.3 
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2.3.3 Primers 
 
Synaptoporin   
1A_F  AAAGAGGGACAAGTGGCTG 
1A_R CCAAATGTGCCTATGGAGAC 
2A_F CCCTCAATCCAGACATTAAGC 
2A_R TGTTTACCCAGAAGTCCCTG 
3A_F CCAGATCACATCCCATTTTG 
3A_R GGGCTCAGGTAACTCCAAAG 
4A_F CTTGTTTCCAGTGCTATGGG 
4A_R GGCCTAGTTTTGTAGGCAAC 
5A_F AAAGTGAAAAGTGATCTTTTGTATTG 
5A_R TGCCACTGAAATGGAAGATG 
1-2B_F  AGGACGGTGGTGCCAAG 
1-2B_R  GACCTCTCCTCACCTGATAGC 
1C_F  TTTGAATGAAGCATTTTGAAAC 
1C_R  TGTGCACATAAAAGTAAGAAGGG 
 
 
FEZF2   
2_1_F CTTTTCCGGAATGCAGAC 
2_1_R AGCCTGGTTGATGACCTG 
2_2_F AAAACCAACTGTGGCGTG 
2_2_R AAAAGGGGCATTCCAGG 
3-4_F GATTGTAGGCCCTCGGAC 
3-4_R AGATCCCTCTTTGCCTTCC 
5_F CTTCCTCCCCACCATTCTAC 
5_R TGTGTGATCTGTTTTCAGGTG 
 
 
ATXN7   
3_F  GAAAGCGAAAGCTAGCCC 
3_R  CAAACGATAGCATCTCTGCC 
4_F  GTGTGCGTCACACTCCTG 
4_R  CGGTCCCAGTGAACTGTC 
5_F  AATGGTTTTATATCAGTCAGAACC 
5_R  CATGCCATCACTGTTCCTTAG 
6_F  AGAATTACATTTGAGATTCGCC 
6_R  TCTCTTTTATATTACTCACAGGCAC 
7_F  TCTGGCTCACCATTCACC 
7_R  ATTTGCTCCCCACGAATG 
8_F  AAAATACATGGAGGAGAGTTTG 
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8_R  CCCAGTCACCCATGTTTATC 
9_F  TTTTGGGATATAAGGCAGACC 
9_R  ACAGTATCTGCAAGTCTCATCTC 
10_F  AGTTAAGGTGGCTGATTCCC 
10_R  CCCTGTCCATGCTGTGTG 
11_F  CTGGGCATGCCAGTGTG 
11_R  CATCAGTCTCACAGGAAATAAAAG 
12-1_F  AAGTCTCTGTGAATGGCTGTG 
12-1_R  TGTTACCGTTGAGGGGTAGG 
12-2_F  CCAGTAGCAGTACCAGTGGC 
12-2_R  TACAAACCAACCAACCAACC 
13_F  CCAGCTTCCTTTGCTCTAAC 
13_R  GCTGGCATTTGAGTTAAGTTC 
14_F  AGTGCAGTGTACAAACGCTTAC 
14_R TCCTCGTTAAAACAACAGCC 
 
 
PRICKLE   
2_F GCCAAGGAATGTGTTTATGG 
2_R CCTCATTTTCCACTGGGG 
3_F CCCAGTAAGTGGGAATAGGC 
3_R AAGGTAACAATTCATAGAAGGCAC 
4_F CTCAGAGTCATGGGCTTCAG 
4_R ATGGGTGAAAAGATGCCAG 
5_F TCATTTATGCACAGCACTGG 
5_R AGACCATGTGTTGGCTATGG 
6_F AGGACCCCATAGCTTTCTTC 
6_R AAACAAAGGTGACCGCATC 
7-1_F CTATGTGTTTCACGTCCCAG 
7-1_R AGTTCTGATGTTGCACTGGC 
7-2_F CAGACACCCAGCCTCAAC 
7-2_R CAGTCACCCAGAGACTACCC 
8-1_F ACAGTGATACCCATTGCTGC 
8-1_R GCCTATCTTTTAACCGGGAG 
8-2_F CACAGGTCCAGGCGTTC 
8-2_R GCGCTTTAACATTTAAAACAGTG 
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2.3.2 Exome sequencing 
1-3μg DNA from an affected proband from family branch 1a (II:4) was used for further 
testing. Exome sequencing was undertaken by our collaborative group at the Beijing 
Genomics Institute (BGI) (Beijing, China) with the Agilent Technologies SureSelect Human 
All Exon Kit. The sequences obtained were aligned to the hg18 reference genome build. The 
sequence variants were compared with the various sources including NCBI dbSNP build 129 
and our in-house database. Variants were categorised and tabulated according to whether they 
were exonic, splicesite or intronic, whether they were heterozygous or homozygous and the 
sequence variant was classified as frameshift, nonsense, missense non synonymous or 
synonymous. Particular scutiny for potentially pathogenic sequence variants was focussed on 
regions of homozygosity previously identified on the SNP arrays.  
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Chapter 3: CHRNG Genotype Phenotype Correlations in 
the Multiple Pterygium Syndromes 
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3 CHRNG Genotype Phenotype Correlations in the Multiple Pterygium Syndromes  
 
A substantial part of this chapter has been published in Vogt et al., 2012. 
 
3.1 Introduction 
 
The MPS are a spectrum of phenotypically heterogeneous disorders ranging from the non 
lethal Escobar variant through to lethally affected fetuses with fetal akinesia and pterygia at 
the most severe end of the spectrum. The aetiology of MPS is also heterogeneous. A 
diagnosis of a specific primary myopathy, metabolic or neurodevelopmental disorder is made 
in a few cases, but until recently, in the underlying aetiology remained unknown in many 
cases (Cox et al., 2003). 
 
 
MPS is most commonly inherited in an autosomal recessive fashion, though autosomal 
dominant, (McKeown and Harris, 1988, Prontera et al., 2006) and X-linked recessive 
pedigrees have been described, (Tolmie et al., 1987).  Recently, genetic studies in autosomal 
recessive families have identified mutations in CHRNG, which encodes the gamma subunit of 
the embryonic nicotinic acetylcholine receptor (AChR) in families with LMPS and/or 
EVMPS, (Morgan et al., 2006, Hoffmann et al., 2006).  
 
3.2 Results 
 
3.2.1 Clinical cohort and CHRNG mutation detection 
 
A cohort of 100 multiple pterygium syndrome (MPS) families of unknown cause were tested 
for the presence of a CHRNG mutation. There were 41 families in which the proband 
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presented with Escobar variant multiple pterygium syndrome (EVMPS). These MPS families 
contained 54 affected individuals.  The affected proband presented with lethal multiple 
pterygium syndrome (LMPS) / fetal akinesia deformation sequence (FADS) in 59 families. 
These families comprised 84 affected individuals. A CHRNG mutation was identified in 
eleven (27%) of the EVMPS families and five (8%) of the LMPS/FADS families. Parental 
consanguinity was noted in 31% of families with CHRNG mutations (3 out of 11 with 
EVMPS and 2 out of 5 with LMPS/FADS). Parents were unrelated in 69% of these families 
(8 out of 11 with EVMPS and 3 out of 5 with LMPS/FADS). The clinical features present 
were collected using a questionnaire tool. Tick boxes were utilised to enable easy completion 
of the questionnaire and to aid analysis of the data. 
 
3.2.2 Clinical features present in the cohort 
 
The clinical features in the 41 Escobar variant MPS families and the 59 LMPS/FADS families 
were compared. Joint contractures were universally present in both groups. Pterygia were 
noted in 50/54 (93%) of the Escobar patients and 58/84 (69%) of those with LMPS/FADS. 
The prenatal features were compared between the two groups. In the LMPS/FADS cases 
cystic hygroma was present in 42/84 (50%), fetal hydrops in 39/84 (46%) and pulmonary 
hypoplasia in 30/84 (36%).  However, in contrast, cystic hygroma and fetal hydrops were 
rarely reported 1/54 (2%) in the nonlethal patients (P< 0.0001 and P<0.0001) and pulmonary 
hypoplasia 2/54 (4%) was only occasionally recognised (P< 0.0001). One of these severely 
affected infants had diaphragmatic eventration and respiratory distress from birth and died at 
4 months of age.  The other was a 3 day old neonatal death. Reduced fetal movements were 
more frequently reported in the LMPS/FADS patients 49/84 (58%) compared with the 14/54  
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(26%) EVMPS patients (P=0.0002). Intrauterine growth retardation was present in 35/84 
(42%) of the LMPS/FADS cases and 8/54 (15%) of the EVMPS cases (P=0.0012). 
Abnormalities were detected on ultrasound examination in 56/84 (67%) of the lethal cases 
compared with 3/54 (6%) of the non lethal families (P<0.0001), Figure 12.  
 
 
 
Figure 12: The prenatal features in the lethal and nonlethal MPS families. 
(Taken from CHRNG Genotype Phenotype Correlations in the Multiple Pterygium Syndromes, Vogt et 
al., 2012). 
 
Cleft palate was identified in over a third 32/84 (38%) of the lethal patients compared with 
7/54 (13%) of the nonlethal group (P=0.0017). Central nervous system manifestations were 
twice as common in the lethal patients (14/84 (17%) and 4/54 (7%) in the nonlethal group 
(P>0.1)), but the difference was not statistically significant. Reduced muscle bulk was 
observed in 24/84 (29%) of the lethal families, compared with 4/54 (7%) of the Escobar cases 
(P=0.0023). Poor postnatal growth was reported in 20/54 (37%) of the non lethal MPS 
families. 
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3.2.3 Clinical features in EVMPS patients with and without a 
detectable CHRNG mutation  
 
CHRNG mutation positive and negative EVMPS cases generally had a similar pattern of 
clinical features (see Table 2). 
 
EVMPS 
(N=17) (%) EVMPS (N=37) (%) 
Feature 
CHRNG mutation 
positive 
CHRNG mutation 
negative   
pterygia 16 94 34 92 
IUGR 0 0 8 22 
polyhydramnios 2 12 2 5 
oligohydramnios 0 0 4 11 
cystic hygroma 1 6 0 0 
pulmonary hypoplasia 2 12 0 0 
hydrops 1 6 0 0 
reduced fetal 
movement 4 24 10 27 
USS abnormalities 
detected  1 6 3 8 
cardiac anomaly 2 12 4 11 
respiratory problems/ 
anomalies 6 35 6 16 
growth 7 41 13 35 
craniofacial 
dysmorphisms 12 71 27 73 
expressionless face 6 35 16 43 
cleft palate 1 6 6 16 
low set ears 6 35 8 22 
malformed ears 2 12 4 11 
reduced muscle bulk 1 6 3 8 
 proximal joint 
contractures 13 76 28 76 
distal joint 
contractures 13 76 30 81 
vertebral anomalies 9 53 21 57 
thoracic anomalies 2 12 10 27 
genital anomalies 3 18 17 46 
CNS anomaly 0 0 3 8 
 
Table 2: Features in CHRNG mutation positive and negative EVMPS patients. 
(Taken from CHRNG Genotype Phenotype Correlations in the Multiple Pterygium Syndromes, Vogt et 
al., 2012). 
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3.2.4 Clinical features in LMPS/FADS patients with and without a 
detectable CHRNG mutation  
 
Developmental central nervous system anomalies were not present in the patients with 
detectable CHRNG mutations (0/7). However, a variety of CNS malformations were 
identified and more than one structural abnormality was described in several patients in the 
CHRNG mutation negative group 14/77 (18%) (P> 0.1).  Cerebellar involvement was present 
in approximately 30% of those with CNS anomalies. Cerebellar hypoplasia was reported in 
5/77 (6%) of cases. Polymicrogyria was identified in 4/77 (5%) and ventricular dilatation in 
3/77 (4%). Although cleft palate was not observed in our CHRNG positive cohort, it was 
frequently noted in those patients without a CHRNG mutation, occurring in 32/77 (42%) 
(P=0.041), see Table 3. 
 
 LMPS/FADS (N=7) (%) LMPS/FADS (N=77) (%) 
Feature 
CHRNG mutation 
positive  
CHRNG mutation 
negative   
pterygia 6 86 52 68 
IUGR 3 43 32 42 
polyhydramnios 3 43 16 21 
oligohydramnios 0 0 5 6 
cystic hygroma 4 57 38 49 
pulmonary 
hypoplasia 3 43 27 35 
hydrops 5 71 34 44 
reduced fetal 
movement 4 57 45 58 
USS abnormalities 
detected  6 86 50 65 
cardiac anomaly 1 14 8 10 
respiratory 
problems/ 
anomalies 0 0 9 12 
growth 0 0 0 0 
craniofacial 
dysmorphisms 6 86 54 70 
cleft palate 0 0 32 42 
low set ears 3 43 41 53 
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malformed ears 1 14 8 10 
reduced muscle 
bulk 1 14 23 30 
 proximal joint 
contractures 5 71 68 88 
distal joint 
contractures 6 86 55 71 
vertebral anomalies 3 43 15 19 
thoracic anomalies 3 43 21 27 
genital anomalies 0 0 16 21 
CNS anomaly 0 0 14 18 
 
 
Table 3: Features in CHRNG mutation positive and negative LMPS/FADS patients. 
(Taken from CHRNG Genotype Phenotype Correlations in the Multiple Pterygium Syndromes, Vogt et 
al., 2012). 
 
3.2.5 Correlation of the clinical features present in the CHRNG 
mutation positive and CHRNG mutation negative MPS patients. 
 
Pterygia were present in 21/24 (86%) of the CHRNG mutation positive EVMPS and LMPS 
patients compared with the mutation negative group where pterygia were observed in 86/114 
(75%) (P=0.28). Cleft palate was only seen in 1/24 (4%) of the CHRNG mutation positive 
patients but was noted in 38/114 (33%) of the CHRNG negative MPS patients (P=0.0025). 
CNS malformations were not associated with the presence of a CHRNG mutation (0/24) and 
were more frequent in the CHRNG mutation negative group 20/114 (P=0.024). 
 
3.2.6 Spectrum of CHRNG mutations identified in the MPS cohort 
 
Table 4 shows the 20 CHRNG mutations detected in the cohort. Homozygous mutations were 
identified in 12 patients whilst compound heterozygous CHRNG mutations were detected in 4 
patients. 7 of the 20 CHRNG mutations identified were novel. Although CHRNG mutations 
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were found throughout the gene, there was a hotspot identified in exon 5 with a recurrent 
CHRNG mutation, and a further recurrent mutation in our cohort detected in exon 7 (see 
Figure 13).  
c.320T>G
p.Val107Gly/hom
c.136C>T
p.Arg46X/hom
c.401_402delCT
p.Pro134ArgfsX43/hom
c.397delT
p.Ser133ProfsX50/hom
c.459dupA
p.Val154SerfsX24/hom & het
c.56-1G>A/hom
c.202C>T
p.Arg68X/het
EVMPS
c.758_759delTG
p.Val253AlafsX44/het
LMPS
c.1283_1302del20
p.Leu431HisfsX22/hom
c.753_754delCT
p.Val253AlafsX44/hom
c.388delG
p.Val130CysfsX53/het
LMPS & EVMPS
c.351-9T>C/hom
c.55G>A/het
c.1132_1136dup
p.Gly380ProfsX39/het
 
Figure 13: Distribution and characteristics of CHRNG mutations in MPS patients. 
(Adapted from CHRNG Genotype Phenotype Correlations in the Multiple Pterygium Syndromes, Vogt et 
al., 2012). 
 
The recurrent mutation c.459dupA (p.Val154SerfsX24) was identified in 6 families from 
different ethnic backgrounds. Affected patients had EVMPS as well as LMPS phenotypes. 
This CHRNG mutation occurred in the homozygous state and in association with a second 
CHRNG mutation in two compound heterozygous individuals. Another recurrent CHRNG 
mutation c.753_754delCT (p.Val253AlafsX44) in exon 7 was less frequently observed. It was 
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present in 3 families with both the non lethal and lethal phenotypes. It occurred as a 
homozygous mutation and in compound heterozygous individuals. Data from the public 
database, Exome Aggregation Consortium (ExAC), which summarises the exome data from 
over 60,000 unrelated individuals, was used to acertain the allele frequencies of the CHRNG 
mutations where available. The recurrent CHRNG mutations identified in my study 
c.459dupA (p.Val154SerfsX24), c.753_754delCT (p.Val253AlafsX44) had a high allele 
frequency of less than 1 in 10, 000 compared to an allele frequency of less than 1 in 100,000 
or no listing for the other mutations detected (Exome Aggregation Consortium (ExAC), 
Cambridge, MA (URL:http://exac.broadinstitute.org) [March, 2016]. 
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Pedigree  Phenotype Ethnic Parental Nucleotide Alterations in Homozygous 
or 
Heterozygous 
Exon/ Exac 
database  
Origin Consanguinity Alterations Coding Sequence Intron allele 
frequency 
            
MPS001 Nonlethal 
and lethal 
Arab Yes c.320T>G p.Val107Gly homozygous 4 not listed 
MPS002 Nonlethal Pakistani Yes c.136C>T p.Arg46X homozygous 2 8.2x10-5 
MPS006 Nonlethal Pakistani Yes IVS4-9T>C (c.351-
9T>C) 
Unknown homozygous IVS4 not listed 
MPS015 Nonlethal White No c.401_402delCT p.Pro134Argfsx43 homozygous 5 9.8x10
-5
 
MPS031 Nonlethal S. 
American/White 
No c.397delT p.Ser133ProfsX50 homozygous 5 8.2x10-6 
MPS033 Nonlethal   No c.459dupA p.Val154SerfsX24 homozygous 5 2.6x10-4 
MPS034 Nonlethal Whitea No c.459dupA p.Val154SerfsX24 homozygous 5 2.6x10
-4
 
MPS037   Nonlethalb S. 
American/White 
No c.202C>T p.Arg68X heterozygous 3 2.5x10-5 
MPS037   Nonlethalb S. 
American/White 
No c.753_754delCT p.Val253AlafsX44 heterozygous 7 1.8x10-4 
MPS038 Nonlethal White (Irish) No c.56-1G>A splicesite homozygous 2 not listed 
MPS042 Nonlethalb White Unknown c.459dupA p.Val154SerfsX24 heterozygous 5 2.6x10-4 
MPS042 Nonlethalb White Unknown c.753_754delCT p.Val253AlafsX44 heterozygous 7 1.8x10-4 
MPS044 Nonlethalb Whitea No c.55G>A p.Gly19Arg heterozygous 1 not listed 
MPS044 Nonlethalb Whitea No c.1132_1136dup p.Gly380ProfsX39 heterozygous 10 not listed 
MPS008 Lethal Turkish Yes c.753_754delCT p.Val253AlafsX44 homozygous 7 1.8x10-4 
MPS011 Lethal  Whitea No c.459dupA p.Val154SerfsX24 homozygous 5 2.6x10-4 
MPS035 Lethalb White No c.388delG p.Val130CysfsX53 heterozygous 5 not listed 
MPS035 Lethalb White No c.459dupA p.Val154SerfsX24 heterozygous 5 2.6x10-4 
MPS036 Lethal Algerian Yes c.1292_1311del20 p.Leu431HisfsX22 homozygous 11 not listed 
MPS039 Lethal Whitea No c.459dupA p.Val154SerfsX24 homozygous 5 2.6x10-4 
 
Table 4: Details of MPS-affected families with CHRNG mutations and sequence variants. 
(Adapted from CHRNG Genotype Phenotype Correlations in the Multiple Pterygium Syndromes Vogt et 
al., 2012). a patients from the United Kingdom; b compound heterozygotes patients. Note 1 MPS001, 
MPS002, MPS006, MPS008, MPS011, MPS015, (Morgan et al., 2006).  
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Haplotype analysis with microsatellite markers (D2S1363, D2S2193 and D2S2344) suggested 
that the three families with the CHRNG c.459dupA mutation did not share a common founder 
mutation (see Table 5). 
 
Pedigree MPS033 MPS034 MPS011  MPS015 MPS031  
CHRNG 
mutation 
c.459dupA c.459dup
A 
c.459dup
A 
 c.401_402delC
T 
c.397delT  
Marker (affected) (affected) (affected) (mother) (affected) (affected 1) (affected 2) 
D2S1363 182 186 178 182 178 
182 
178 186 186 
D2S2193 261 251 263 253 241 253 
239  
255 267 253 255 253 257 
D2S2344 196 196 196 196 196 190 190 
 
Table 5: Haplotype analysis of CHRNG c.459dupA mutation positive families. 
(Taken from Vogt et al., 2012). 
 
In addition sequence variants of uncertain pathogenicity were detected during the analysis. 
These are shown below in Table 6.  
 
Pedigree  
Phenotype Ethnic 
Origin 
 
Nucleotide 
Alterations 
 
Alterations in 
Coding 
Sequence 
 
Homozygous 
or 
Heterozygous 
Exon/ 
Intron 
 
Parental 
Consanguini
ty 
 
MPS028 
 
Lethal 
 
? African IVS7-13 T>C  unknown 
 
heterozygous 
 
7 
 
Unknown 
MPS028 
 
Lethal 
 
? African 
IVS7-
23insCCTGCCT
G  unknown 
 
heterozygous 
7 
 
Unknown 
MPS029 
 
Lethal Turkish c.367G>A p.Glu123Lys 
 
heterozygous 5 
 
Yes 
MPS30 
 
Lethal 
 
White c.55+27G>A   unknown 
 
heterozygous 1 
 
Yes 
MPS032 
 
Nonlethal 
 
S. American c.299T>G p.Leu100Arg 
 
homozygous 3 
 
Unknown 
MPS043 
 
Nonlethal 
 
African c.1259C>T p.Pro420leu 
 
heterozygous 
 
10 
 
Unknown 
MPS046 
  
Brazil c.82C>T p.Arg28Cys 
 
heterozygous 1 
 
Unknown 
 
Table 6: Details of MPS-affected families with CHRNG sequence variants. 
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3.2.7 Intrafamilial Variation in CHRNG mutation positive families 
 
The MPS phenotype was assessed in the affected patients with CHRNG mutations 
incorporated into our study. Within the EVMPS cohort, all 10 affected siblings subsequently 
born into these 41 families were affected with Escobar variant MPS. Although the 1
st
 and 2
nd
 
siblings affected with MPS in one CHRNG positive family died in the neonatal period and 
early infancy, the 3
rd
 affected sibling was not affected with lethal MPS, (Morgan et al., 2006). 
However the significance of the family history in this single family is unclear. Factors such as 
the severity of the congenital malformations and the availability of medical care may have 
influenced the outcome in these individuals. In this family there were 4 other cousins with 
Escobar variant MPS and one deceased cousin. In another family, two siblings with nonlethal 
MPS had a cousin who was severely affected and died in infancy. In the CHRNG mutation 
negative group there was one family with an affected child who died at 3 years old (about 
which little detail is available) who had an affected sibling who survived. Three siblings 
affected with Escobar variant MPS in one family had 2 cousins that died in early childhood, 
about which there are no further details.  
 
In our cohort the proband presented with LMPS/FADS in 59 of the families. All of the 25 
affected siblings had an LMPS/FADS phenotype (25/25). This included 6 families with 3 
lethally affected siblings. In one CHRNG mutation positive kindred a sibling died in the 
neonatal period while the other was diagnosed with fetal hydrops in early pregnancy. 
Although the presentations were variable, they were both in the lethal spectrum. Overall, the 
chance of a similar MPS phenotype arising in further affected siblings is estimated to be 
10/12+25/25=35/37 = 95% (95% CI 81-99 %).  
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3.3 Discussion 
 
The discovery of gamma subunit (CHRNG) acetylcholine receptor mutations in MPS have 
provided valuable insights into the pathogenic mechanisms underlying this condition.   
Mutations in the embryonal AChR, CHRNG, result in severe fetal akinesia in early to mid-
pregnancy, causing pterygia and other developmental anomalies in MPS. As the switch to the 
adult AChR occurs in the third trimester of pregnancy, postnatal muscle weakness and 
fatigability is not a feature of CHRNG positive MPS. This contrasts with the congenital 
myasthenic syndromes, another group of AChR deficiency conditions.   
 
CHRNG mutations were found in 27% of EVMPS and 8% of LMPS/FADS kindreds. The 
actual detection rate may be lower because patients with alternative diagnoses, estimated to be 
present in about half of cases (Witters et al., 2002), were not included in our cohort.  
However, CHRNG heterozygous exonic deletions and mutations outside the coding exons and 
flanking sequences would not have been detected by our mutation analysis. 
 
The EVMPS and LMPS/FADS cases had a similar CHRNG mutation spectrum, thus the 
severity of the phenotype did not appear to correlate with the mutation type or its position in 
the gene. The same CHRNG mutation (for example, the c.459dupA mutation) was identified 
in both the lethal and Escobar variant families. As interfamilial phenotypic variability was 
more marked than intrafamilial variability, this may have been due to the effect of genetic and 
environmental modifiers.  The CHRNG mutations c.459dupA and c.753_754delCT were 
recurrent in our cohort. However, there was no evidence to support a common haplotype and 
a founder mutation affect.  
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Cystic hygroma and fetal oedema are frequent in LMPS/FADS, (de Die-Smulders et al., 1990, 
Hall, 1984), and the absence of these features in the EVMPS cohort suggests that they are 
markers for more severe fetal akinesia. Pulmonary hypoplasia was not observed in the 
EVMPS probands. It was detected in 2 of the 12 siblings however this may have been due to a 
more detailed assessment following the birth of an affected child. Cleft palate was identified 
in over a third of the LMPS/FADS patients but was less common in the EVMPS cases, thus it 
may represent more severe akinesia in that group. Cleft palate was more often observed in the 
CHRNG negative EVMPS patients occurring in 6/37 (16%) and 1/17 (6%) of the CHRNG 
positive patients. Pterygia arise as a consequence of hypokinesia and have been observed 
before the development of fetal oedema (Machin, 1989). However, fetal oedema may inhibit 
movement further and exacerbate muscle hypoplasia resulting in the associated congenital 
anomalies and characteristic craniofacial features, (Hall, 1984). 
 
Central nervous system (CNS) anomalies in LMPS/FAD suggest that a CHRNG mutation is 
unlikely. Although CNS malformations were not reported in CHRNG positive patients, a fifth 
of the CHRNG negative group had one or more CNS anomalies. Cerebellar hypoplasia, 
polymicrogyria or ventricular dilatation were most frequently noted. Thus CNS abnormalities 
may indicate a different underlying pathogenesis for the MPS phenotype in these patients. 
 
Growth retardation is frequent in LMPS/FADS, as previously reported (Gillin and Pryse-
Davis, 1976, Chen et al., 1984, Chen et al., 1980).  However in the EVMPS families poor 
postnatal growth was observed in over a third.  Pterygia were almost universal in MPS 
patients with a CHRNG mutation (21/24), thus pterygia predicted the presence of a CHRNG 
mutation.  
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Phenotypic variation of affected children within families as well as between families is well 
documented in MPS, (Ramer, 1991).  Clinically it is important where possible for parents to 
have information about the chance of a lethally affected sibling being born to a family with a 
child with EVMPS, or the chance of a nonlethally affected baby arising in a family who have 
previously had a lethally affected baby. From the analysis there is a 95% chance that a 
subsequent sibling will have the same MPS phenotype (EVMPS or LMPS) as the proband, 
although there is less concordance for more distant relatives.  
 
The CHRNG mutations were included in the new Locus Specific Database as outlined in the 
following chapter. As a significant proportion, approximately two thirds of our cohort 
remained without a molecular diagnosis, further candidate gene studies were undertaken on 
the CHRNG negative families as described in the following chapters.  
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Chapter 4: Mutations in CHRNG – A New Locus-Specific 
database (LSDB) 
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4 Mutations in CHRNG – A New Locus-Specific database (LSDB) 
 
4.1 Introduction 
 
4.1.1 CHRNG Database 
 
A Locus-Specific sequence variation Database (LSDB) has been established for CHRNG 
mutations using the Leiden open (Source) Variation Database (LOVD) software (Fokkema et 
al., 2005). The aim of the database was to provide clinicians, laboratory scientists and 
researchers with the currently available CHRNG mutation information.   
 
The embryonic acetylcholine receptor subunit gene CHRNG is located on chromosome 2 and 
comprises 12 exons. Mutations in CHRNG have been detected in a significant proportion of 
those affected with lethal and Escobar variant multiple pterygium syndrome (MPS) (Morgan 
et al., 2006, Hoffmann et al., 2006, Vogt et al., 2012). A variety of homozygous and 
compound heterozygous CHRNG mutations have been detected throughout the gene. Follow-
up investigations of the CHRNG sequence variants detected may confirm segregation in the 
family and the absence of the CHRNG variant in ethnically matched control samples. 
However, as this gene is only expressed in fetal life, the lack of functional studies can make it 
difficult to determine pathogenicity of a sequence variant. This has implications for genetic 
counselling, the availability of prenatal diagnosis and carrier testing for affected families.  The 
establishment of a locus specific database (LSDB) was considered to record the CHRNG 
mutations detected and to to try and improve our understanding of CHRNG sequence variants 
and aid in interpretation of the results for families.  
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The LSDB database enables easy submission, curation and maintenance of the CHRNG 
variants online, to ensure that the nomenclature complies with standardised Human Genome 
Variation Society (HGVS) guidelines. Numbering of the cDNA sequence was undertaken 
using the National Centre for Biotechnology Information (NCBI) accession number 
NM_005199.4, where CHRNG cDNA sequence +1 equalled A of ATG in accordance with 
the Human Genome Variation Society (HGVS) guidelines. The database included details 
about the DNA sequence variant, the exon, the subsequent predicted effect on the protein 
sequence, the type of mutation and its pathogenicity. Mutations were graded according to the 
type of mutation. Pathogenicity was assigned based on the classification of the mutation and 
its association with disease. All the sequence variants were detected in affected patients, 
segregated with the disease and were not present in controls. As CHRNG is only expressed in 
fetal life, RNA studies were not undertaken in any of the cases, due to the lack of availability 
of appropriate samples. The source of the material, the technique for mutation detection as 
well as clinical phenotype was linked to a unique patient identifier.   
 
The database included published and unpublished novel as well as recurrent CHRNG 
sequence variants. Previously reported CHRNG mutations were renamed to concur with the 
HGVS nomenclature, however published mutation annotation is included for cross-
referencing purposes. A PubMed hyperlink to the reference was added for published sequence 
variants where possible. Each CHRNG entry was allocated a unique identifier and the likely 
pathogenicity and clinical features information was added. Unpublished mutations and 
variants can be submitted by other contributors following registration for a login and 
password. Before this information is shared, it is curated as previously described (Fokkema et 
al., 2005, Bayley et al., 2005). The CHRNG LSDB of published and unpublished sequence 
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variants together with information about the likely pathogenicity and clinical phenotype thus 
provides an invaluable resource for clinician and scientists working with families with this 
group of conditions. This database is registered on the Human Genome Variation Society 
(HGVS) locus specific database list and can be accessed online at 
http://www.lovd.nl/CHRNG (Figure 14). 
 
 
Figure 14: CHRNG mutation public access database 
 
4.1.2 Contents of CHRNG Database 
 
The database currently contains 34 entries from 29 families: 32 pathogenic mutations and 7 
variants of unknown clinical significance in the CHRNG gene (Table 7). The DNA sequence 
variants were classified in 24% as deletions, in 26% as duplications and in 50% as missense 
substitutions. The protein variants are classified as nonsense in 12%, frameshift in 47%, 
duplications in 3%, substitutions in 32% and unknown in 6%. 
 
Homozygous pathogenic CHRNG mutations from 19 families and pathogenic compound 
heterozygous mutations from 11 families are included on the database. However the second 
variant c.481G>A; W139X from EG-3 (Hoffmann et al., 2006) was omitted due to difficulties 
in annotating the variant. 13 previously published CHRNG mutations were included: 4 
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frameshift, 3 nonsense, 1 duplication, 2 splicesite and 3 missense mutations (Morgan et al., 
2006, Hoffmann et al., 2006).   
 
4.1.3 Novel CHRNG mutations 
 
12 novel CHRNG mutations were added to the database: 1 nonsense, 4 frameshift and 2 
splicesite mutations (included in our recent publication (Vogt et al., 2012) and 5 missense 
sequence variants of unknown pathogenicity.  
 
4.1.3.1 Frameshift mutations 
 
Four frameshift mutations were identified.c.388delG;p.Val130CysfsX53 in exon 5 was 
detected with the c.459dupA;p.Val154SerfsX24 mutation in a patient with lethal MPS. A 
homozygous c.1292_1311del20;p.Leu431HisfsX22 mutation in exon 11 was also identified in 
a lethally affected individual. The remaining three mutations were detected in Escobar variant 
families. The c.397delT;p.Ser133ProfsX50 mutation in exon 5 was identified in the 
homozygous state. The mutation c.1132_1136dup;p.Gly380ProfsX39 in exon 10 was 
identified in a  compound heterozygote together with a novel splicesite mutation 
c.55G>A;pGly19Arg.  
 
4.1. 3.2 Nonsense mutations 
 
One Escobar variant patient identified was a compound heterozygote with a novel nonsense 
mutation, c.202C>T;p.Arg68X) in exon 3 and a frameshift CHRNG mutation 
c.753_754CT;p.Val253AlafsX44 mutation in exon 7. 
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4.1.3.3 Splicesite mutations 
 
Two splicesite mutations were identified in CHRNG. A homozygous splicesite mutation was 
located at the 5’end of the gene at the exon 2 intron/exon boundary (c.56-1G>A) in a patient 
with Escobar variant MPS. The second splicesite variant c.55G>A;pGly19Arg was located at 
the most 3’ nucleotide of exon 1. This sequence variant was occurred with an exon 10 
frameshift mutation c.1132_1136dup;p.Gly380ProfsX39 in an Escobar variant MPS patient.  
 
4.1.3.4 Missense Mutations 
 
The homozygous missense mutation c.299T>G;p.Leu200Arg in exon 4 was detected in a 
patient with Escobar variant MPS.  Four other heterozygous missense variants of unknown 
pathogenicity were identified. c.82C>T;p.Arg28Cys in exon 2 was noted in a patient with 
Escobar variant MPS and c.1259C>T;p.Pro420Leu in exon 10 was detected in another 
affected individual. c.367G>A;p.Glu123Lys in exon 5 and c.1516C>T;p.Pro506Ser in exon 
12 were each present in a patients with lethal variant MPS.  
In total 25 unique CHRNG sequence variants are included in the database (Table 7). Of these 
18 are reported as pathogenic and there are 7 variants of unknown significance. 
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100
entries per page 
 
Exon 
 
 
 
 
DNA change 
 
  
 
 
 
 
Protein change 
 
 
 
 
 
Type 
 
 
 
 
 
Variant remarks 
 
 
 
 
 
DB-ID 
 
 
 
 
       
01 c.13C>T    p.Gln4X Nonsense Homozygote 
Previously 
reported:c.DNA 
13C>T, Mature 
protein after 
signal peptide 
cleavage Q-18X. 
CHRNG_00042 
01 c.55G>A    p.Gly19Arg  Splicesite compound 
heterozygote 
CHRNG_00053 
02 c.56-1G>A    - Splicesite homozygote CHRNG_00056 
02 c.82C>T    p.Arg28Cys Missense Heterozygote CHRNG_00052 
02 c.136C>T    p.Arg46X Nonsense Homozygote CHRNG_00002 
03 c.202C>T    p.Arg68X Nonsense Compound 
Heterozygote 
CHRNG_00035 
04 c.256C>T    p.Arg86Cys Missense Compound 
heterozygote 
Previously 
reported:cDNA 
256C->T, Mature 
protein after 
signal peptide 
cleavage R64C. 
CHRNG_00047 
04 c.299T>G    p.Leu100Arg Missense Homozygote CHRNG_00032 
04 c.300_308dup   p.Arg101_Pro103d
up 
Other Duplication. 
Compound 
heterozygote. 
Previously 
reported:CDNA 
300dup(9), 
mature protein 
after signal 
peptide cleavage 
79dup(3). 
CHRNG_00037 
04 c.320T>G    p.Val107Gly Missense Homozygote CHRNG_00001 
IVS
4 
c.351-9T>C    - Splicesite Homozygote 
Previously 
reported as IVS4-
9T->C, possible 
splicesite 
mutation. 
CHRNG_00044 
05 c.367G>A    p.Glu123Lys  Missense Heterozygote CHRNG_00051 
05 c.388delG    p.Val130CysfsX53 Frameshift Compoound CHRNG_00049 
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heterozygote 
05 c.397delT    p.Ser133ProfsX50 Frameshift Homozygote CHRNG_00031 
05 c.401_402delCT   p.Pro134ArgfsX43 Frameshift Homozygote 
Previously 
reported: 
c.401_402delCT, 
p.Pro134ArgfsX
34. 
CHRNG_00048 
05 c.459dupA 
  (Reported 6 times) 
  p.Val154SerfsX24 Frameshift Homozygote CHRNG_00033 
07 c.715C>T 
  (Reported 2 times) 
  p.Arg239Cys Missense Homozygote 
Previously 
reported:cDNA 
715C->T, Mature 
protein after 
signal peptide 
cleavage R217C. 
CHRNG_00043 
07 c.753_754delCT 
  (Reported 4 times) 
  p.Val253AlafsX44 Frameshift Homozygote. 
Previously 
reported 
p.Pro251ProfsX4
6 
CHRNG_00008 
08 c.807dupT    p.Gly270TrpfsX28 Frameshift Homozygote 
Previously 
reported:cDNA 
807insT, Mature 
protein after 
signal peptide 
cleavage âˆ†248-
274, 275X. 
CHRNG_00045 
10 c.1132_1136dup   p.Gly380ProfsX39 Frameshift compound 
heterozygote 
CHRNG_00054 
10 c.1249G>C    p.Glu417Gln Splicesite Homozygote 
Previously 
reported:cDNA 
1249G->C, 
Mature protein 
after signal 
peptide cleavage 
âˆ†395-418, 
419X. 
CHRNG_00046 
10 c.1259C>T    p.Pro420Leu  Missense Heterozygote CHRNG_00055 
11 c.1292_1311del20    p.Leu431HisfsX22 Frameshift Homozygote CHRNG_00041 
12 c.1408C>T    p.Arg470X Nonsense Compound 
heterozygote. 
Previously 
reported:CDNA 
CHRNG_00038 
94 
1408C->T, 
mature protein 
after signal 
peptide cleavage 
R448X. 
12 c.1516C>T    p.Pro506Ser  Missense Heterozygote CHRNG_00050 
 
Table 7: LOVD CHRNG database unique sequence variants. 
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4.2 Database Analysis 
 
Although most CHRNG positive MPS patients studied to date have homozygous CHRNG 
mutations, six affected patients were compound heterozygotes. This may reflect the original 
recruitment methods favouring consanguineous families for autozygosity mapping studies. 
However, this trend can be reassessed in the future with the collection of further patient data. 
 
Mutations have previously been reported throughout CHRNG the gene, with no observed 
mutational hot spot (Hoffmann et al., 2006, Morgan et al., 2006). However, recurrent 
mutations have more recently been identified suggesting previously unrecognised mutational 
hotspots (Vogt et al., 2012). The exon 5 frameshift mutation c.459dupA;p.Val154SerfsX24 
mutation has been reported in the published literature (Morgan et al., 2006) and was identified 
in six patients from unrelated white families. Escobar-variant and lethal phenotypes were 
associated with both 459dupA;p.Val154SerfsX24 homozygotes and compound heterozygotes. 
The c.753_754CT;p.Val253AlafsX44 mutation in exon 7 was detected in four unrelated 
patients. It occurred in a homozygous state as well as in compound heterozygotes. 
Homozygous c.753_754CT;p.Val253AlafsX44 mutations were associated with an Escobar 
variant phenotype in one family and lethal MPS in another. Compound heterozygous 
c.753_754CT;p.Val253AlafsX44 mutations were identified in two other Escobar families. 
The homozygous mutation c.715C>T;p.Arg239Cys in exon 7 was reported in two families 
with lethal and Escobar-variant MPS.  
 
Lethal and non lethal MPS phenotypes occurred in association with four CHRNG mutations 
(c.320T>G;p.Val07Gly, c.459dupA;p.Val154SerfsX24 and c.753_754CT;p.Val253AlafsX44, 
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c.715C>T;p.Arg239Cys). Although the lethal phenotype was not recorded in associated with 
mutations 5’ to exon 4, this is more likely to be due to the small sample size rather than a 
positional effect of the mutation.  
Five missense variants of unknown pathogenic significance were detected. A homozygous 
missense variant c.299T>G;p.Leu100Arg was observed in an Escobar patient. However, this 
family was not available for further study to clarify the significance of this CHRNG variant. 
Four missense variants were determined in the heterozygous state. This may be due either to 
failure to detect a second CHRNG mutation (e.g. an exon deletion), the presence of a mutation 
in a second as yet unidentified gene, or because the variant is not implicated in MPS.   
 
CHRNG sequence variants have been included in the Locus-Specific database. This may be a 
useful tool for clinicians and laboratory scientists analysing CHRNG sequence information. 
Information obtained from the pooling of genetic variants for rare conditions can aid with 
interpretation of patient results.  Confirmatory diagnostic genetic testing and CHRNG prenatal 
diagnosis is available for a proportion of families. However, the inter- and intrafamilial 
phenotypic variability and lack of clear genotype phenotype correlation continues to cause 
difficulties in genetic counselling. The shared database of CHRNG mutations may assist this 
process for families affected with this group of conditions. It is envisaged that this will be a 
useful tool for laboratory staff, clinicians and researchers working with patients with this 
group of conditions. With the transfer of the CHRNG testing to the diagnostic genetic testing 
laboratory service, curating and maintenance of database may be more efficiently managed by 
the diagnostic service laboratory team in the future. 
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Chapter 5: Candidate Gene Analysis of CHRNA1, 
CHRNB1, CHRND and RAPSN  
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Chapter 5: Candidate Gene Analysis of CHRNA1, CHRNB1, CHRND and RAPSN  
 
 
A substantial part of this chapter has been published in Vogt et al., 2008. 
 
5.1 Introduction 
 
Multiple pterygia are occasionally present in children with arthrogryposis and in fetuses with 
fetal akinesia syndrome (Hall et al., 1982b). The embryonal gamma acetylcholine receptor 
subunit gene (CHRNG) has an important role in prenatal muscle development, thus the 
detection of CHRNG mutations in a significant proportion of patients with lethal MPS 
patients suggested that pterygia resulted from early onset fetal akinesia.  Fetal akinesia 
deformation sequence syndrome (FADS) is characterised by a variable combination of fetal 
akinesia, intrauterine growth retardation, developmental defects (e.g. cystic hygroma, lung 
hypoplasia, cleft palate, cryptorchidism, intestinal malrotation, cardiac defects), 
arthrogryposis and, in some cases, limb pterygia (Hall et al., 1982b, Hall, 1984). FADS is 
clinically and genetically heterogeneous. Due to the phenotypic variability observed in the 
CHRNG positive cohort it was hypothesised that mutations in other AChR-related genes 
predicted to cause prenatal as well as postnatal neuromuscular transmission deficits might 
also cause fetal akinesia and pterygia. Patients referred for CHRNG mutation analysis without 
pterygia were also included in the analysis.   
 
 
5.1.1 Selection of candidate genes 
 
A candidate gene approach was used to select genes, mutations in which were likely to result 
in severe fetal akinesia. From the knowledge of the critical importance of the AChR, other 
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genes involved in neuromuscular junction transmission were considered.  The skeletal muscle 
nicotinic AChR is a pentameric transmembrane protein that exists in two forms. The adult 
AChR consists of two alpha and one beta, a delta subunit and an epsilon subunit (α2βεδ) 
whereas the embryonic AChR has two alpha and one beta, one delta and a gamma subunit, 
(α2βδ) (Mishina et al., 1986, van der Slot et al., 2003, Noda et al., 1983, Shibahara et al., 
1985). As our patients had features of fetal akinesia, genes encoding CHRNA1, CHRNB1, 
CHRND prenatally expressed components of the embryonic AChR were selected for 
investigation. RAPSN was also included because it encodes a post synaptic protein involved in 
the development of specialised post-synaptic neuromuscular junction structures and has an 
essential role in AChR clustering (Sanes and Lichtman, 2001).  
 
5.2 Results 
 
Fifteen probands with no evidence of a germline CHRNG mutation were selected for mutation 
analysis of the coding sequence and flanking intronic sequence of CHRNA1, CHRNB1, 
CHRND and RAPSN. The clinical features of the 15 families are summarised in Table 8.  
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Family 
ID 
Ethnic 
Origin 
Parental 
Consanguinity Phenotype 
RAPSN Sequence 
Variant 
CHRND Sequence 
Variant 
            
MPS013 Pakistani Yes LMPS     
MPS012 Bengali Yes 
AMC, no 
pterygia 
 
  
MPS014 White No LMPS     
MPS016 White No LMPS     
MPS017 White  No LMPS   IVS8-37G>A het 
MPS018 White  No LMPS   IVS8-37G>A het 
MPS019 Indian Yes LMPS     
MPS020 White No LMPS     
MPS021 White  No LMPS     
MPS022 Afrikaner No LMPS IVS2-15C>T het   
MPS023 White  No LMPS     
MPS010 Pakistani Yes 
AMC, no 
pterygia     
MPS009 Pakistani Yes LMPS     
MPS024 Palestinian Yes LMPS     
MPS025 Ethiopian No LMPS     
 
Table 8: Clinical features and sequence variants detected in RAPSN and CHRND. 
Sequence variants were not detected in the acetylcholine receptor subunit genes CHRNA1 or CHRNB1. 
 
No pathogenic mutations were detected in CHRNA1, CHRNB1 or CHRND. However, a 
RAPSN frameshift mutation was detected in a consanguineous family with three affected 
children (Figure 15). Both parents were heterozygous for a C.1177_1178delAA mutation and 
all three affected children were homozygous for the mutation.  
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Control sequence 1177delAA homozygote 1177delAA heterozygote
 
Figure 15: Sequence traces for normal control, homozygote and heterozygote carrier of RAPSN frameshift 
mutation. 
 
Review of the clinical records revealed that the consanguineous Dutch couple presented when 
evidence of the fetal akinesia sequence was detected at 19 weeks of gestation in twin male 
fetuses. On ultrasound examination both fetuses had features of the fetal akinesia deformation 
sequence. They had joint contractures affecting the hands, elbows and feet and micrognathia. 
There were no respiratory movements and the thorax appeared small. There was mild 
hydrops. The pregnancy was terminated at 23 weeks of gestation. Post mortem examination 
revealed monochorionic, monoamniotic twins with no evidence of growth retardation [Twin 1 
0.587 kg (~50 centile) and Twin 2: 0.665 kg (>50 percentile)]. They had mild hydrops with 
hydrothoraces and subcutaneous oedema of the head, neck, back of the shoulders and 
proximal extremities. Both twins appeared dysmorphic with a flat facial profile, 
hypertelorism, moderate micrognathia and a short broad neck. The lungs were hypoplastic 
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and the diaphragm was thin and membranous. Both twins had hyperextended wrists and 
flexed fingers. The ankles were fixed in a varus position and the toes hyperextended. No 
pterygia were detected. The couple had a further similarly affected female pregnancy. Fetal 
akinesia sequence was detected on ultrasound at around 19 weeks of gestation and the 
pregnancy was terminated at 23 weeks of gestation. On post mortem examination the fetus 
had subcutaneous oedema of the head, neck and shoulders. Facially there was micrognathia, 
low set ears, a short nose, a short philtrum, thin lips and a short broad neck. The elbows were 
flexed and the wrists hyperextended. There was overlapping of the second and third fingers on 
both sides.  No pterygia were identified. The lungs were hypoplastic (Figure 16). 
 
  (i)    (ii) 
 
 
      
           (iii) 
Figure 16: Clinical presentation of fetal akinesia defomation sequence in siblings 
Homozygous RAPSN mutations (i) and (ii) affected male twins and (iii) affected singleton fetus. 
 
Neuromuscular histopathological examination failed to identify a specific underlying cause 
for the fetal akinesia. The brain and spinal cord were of normal morphology on macroscopic 
and microscopic examination. The muscle histopathology revealed muscle fibres of varying 
103 
diameters (considered to be normal for the gestational age) with a normal striated pattern and 
no fibrosis in the male twins. The muscle fibres were of normal diameter for gestational age in 
the female singleton. No abnormalities were detected on enzyme analysis. On electron 
microscopy the striated muscle appeared well developed. All three cases showed occasional 
muscle fibres with centrally located nuclei, but this appearance was observed in <5% of the 
muscle fibres examined and was not diagnostic of a myotubular myopathy. Chromosome 
analysis was normal and molecular testing for congenital myotonic dystrophy was negative. 
The couple also have two healthy children. 
 
The c.1177-1178delAA mutation was predicted to cause a frameshift after residue 392 of 
rapsyn resulting in a mutant rapsyn that is 62 amino acids longer than the wild type (Figure 17 
and 18). Functional analysis of the RAPSN mutation associated with fetal akinesia sequence 
below was undertaken by Professor Beeson’s team (Hayley Spearman and Judy Cossins), as 
published in the clinical report by (Vogt et al., 2008).  
 
 
Figure 17: DNA sequences and translations of exon 8 for wild-type and mutant human rapsyn. 
 
In the wild-type sequence, the two nucleotides that are deleted in the mutant are shown in red. As a 
consequence of the frameshift, mutant rapsyn is 62 amino acid residues longer than wild-type (asterisk 
indicates termination codon). 
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Figure 18: Diagram of wild-type and mutant rapsyn tagged with EGFP at the carboxyl terminus. 
 
Wild-type or mutant rapsyn cDNA without a stop codon were cloned into pEGFP-N1 (Clontech) so that 
EGFP was in-frame with rapsyn. Mutagenesis to delete the two adenine residues was carried out with the 
QuikChange mutagenesis kit purchased from Stratagene and was confirmed by DNA sequencing. The 
frameshift in the c.1177-1178delAA mutant extends the length of the protein by 62 amino acid residues, 
and so the corresponding 30UTR was included in this construct. 
 
 
Professor Beeson’s group tagged wild-type and mutant rapsyn with EGFP in-frame at their C 
termini and cotransfected with cDNAs encoding the human AChR into the muscle cell line 
TE671. TE671 cells were maintained at 37_C in DMEM (Sigma-Aldrich) supplemented with 
10% FCS (TCS Cellworks) and 100 units/ml each of penicillin G and streptomycin (PS) 
purchased from Invitrogen. TE671 cells do not express detectable levels of endogenous 
rapsyn polypeptide. After transfection, effects on AChR clustering were studied. Thus, TE671 
cells were seeded at 2.3 x 10
5
 cells per well on coverslips in 6-well plates and the following 
day were transfected with a total of 3 mg DNA per well via calcium phosphate precipitation. 
Amounts of DNA used per well was 1 mg AChR α-subunit DNA, 0.5 mg each of AChR β-, δ-
and ε-subunit cDNA, and 0.5 mg of rapsyn cDNA or pcDNA3.1-hygro for ‘‘no rapsyn’’ 
control transfections. Transfections with only rapsyn and no AChR were carried out with 3 
mg/well of rapsyn expression plasmids. The next day, the media was replaced with fresh 
medium. Whereas transfection with wild-type rapsyn resulted in the colocalization of rapsyn 
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and AChR on the cell surface in small dense clusters, transfection with rapsyn-392+82-EGFP 
resulted in low levels of EGFP fluorescence within the cells and unclustered AChR expressed 
uniformly along the cell surface (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Rapsyn mutation c.1177-1178delAA does not cluster the AChR. 
TE671 cells were cotransfected with cDNAs encoding rapsyn-EGFP or rapsyn-1177delAA-EGFP and the 
human AChR subunits. AChR was detected with mAb B3 directed against the AChR β subunit. 28 Cells 
were fixed with 3% paraformaldeyde at room temperature for 20 min, washed three times with PBS, and 
incubated with secondary antibody Alexa Fluor 594 goat anti-mouse IgG (HþL) diluted 1:1000 in PBS 
containing 1% BSA (Molecular Probes). Cells were washed 33 in PBS and mounted in fluorescent 
mounting media (Dako Cytomation). Microscopy was performed on an Olympus BX60 wide-field 
fluorescence microscope, and images were captured with Openlab software (Improvision). 
 
To examine this observation further, a time course of rapsyn expression was performed 
following transfection by western blots on cell extracts. Confirming the observation from 
WT
1177del2
AChR rapsyn merge
C
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fluorescence microscopy the mutant rapsyn was present at much lower levels and by three 
days post-transfection could not be detected (Figure 20 and 21). The results suggest that the 
mutant rapsyn is rapidly degraded. It is likely that in the patient fetal AChR are not clustered 
due to the loss of rapsyn, which results in the disruption of the neuromuscular synapse 
formation and neuromuscular transmission, which in turn results in severe fetal akinesia.  
 
(Figure 20) 
 
 
 
(Figure 21) 
 
 
 
 
Figure 20: Western blot of rapsyn-EGFP and rapsyn-1177delAA-EGFP expressed in TE671 muscle cells. 
 
TE671 cells were transfected with wild-type or mutant rapsyn-EGFP, and 48 hr later, total cell lysate was 
analysed by Western blotting. Rapsyn was detected by mAb clone 1234 (Abcam) followed by anti-mouse-
HRP and ECL (Amersham). As a control, a-tubulin was detected on the same western blots with a mAb 
(Sigma-Aldrich) followed by anti-mouse-HRP and ECL. The experiment was performed twice; one 
example is shown.  
 
Figure 21:The ratio of rapsyn:a-tubulin was obtained by densitometric scanning of western blots. 
Whereas rapsyn-EGFP gave robust expression on days 1 and 2, rapsyn-1177delAA-EGFP was barely 
detectable throughout the time course. 
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5.3 Discussion  
 
After identifying that mutations in the CHRNG gene that encodes the gamma subunit of the 
embryonal acetylcholine receptor may cause the non-lethal Escobar variant (EVMPS) or the 
lethal form (LMPS) of multiple pterygium syndrome (MPS), it was also considered that  
CHRNG mutations and mutations in other components of the embryonal acetylcholine 
receptor may present with fetal akinesia deformation sequence (FADS) without pterygia.  
 
Mutations in AChR subunits have previously been associated with the congenital myasthenic 
syndromes (CMS). These are a heterogeneous group of inherited neuromuscular transmission 
disorders characterised by fatiguable muscle weakness.  CMS can be caused by mutations in 
CHRNA1, CHRNB1, CHRND and CHRNE, as altered AChR channel kinetics or severely 
reduced AChR in the postsynaptic membrane results in AChR deficiency (Engel et al., 2003, 
Jurkat-Rott and Lehmann-Horn, 2005). Mutations in CHRNE, the postnatally expressed 
subunit of the AChR, most commonly result in a mild phenotype, whereas AChR deficiency 
mutations in the prenatally expressed subunits CHRNA1, CHRNB1 and CHRND are rare and 
cause a severe phenotype. Although the clinical presentation of CMS and MPS are distinct, 
two siblings with a fast channel CMS due to heteroallelic mutations in CHRND had 
arthrogryposis (Brownlow et al., 2001). One sibling had reduced fetal movements in utero. At 
birth he was noted to have joint contractures in his hands and bilateral ptosis. He died at the 
age of 5 months from bronchopneumonia. His sister had also reduced in fetal movements and 
was noted to have flexion contractures of the interphalangeal joints at birth. She was floppy 
with a weak cry and feeding difficulties. She had recurrent severe respiratory compromise. 
Neurophysiology was consistent with CMS and there was improvement in strength with 
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pyridostigmine treatment. Genetic analysis identified the presence of two pathogeneic 
compound heterozygous CHRND mutations (Brownlow et al., 2001).  
 
CMS can also result from mutations in other postsynaptic proteins involved in neuromuscular 
transmission or in the formation and maintenance of the neuromuscular junction. Recessive 
germline mutations in RAPSN have been reported in patients with CMS and AChR 
deficiency, (Ohno et al., 2002, Burke et al., 2003, Maselli et al., 2003, Muller et al., 2003). 
RAPSN has been mapped to chromosome 11p11.2p11.2 and contains 8 exons (Buckel et al., 
1996). The RAPSN gene product (Rapsyn; receptor-associated protein of the synapse) has a 
key role in the clustering of AChRs at the neuromuscular synapse (Apel et al., 1995). 
 
Rapsyn is a 43kDa complex protein. It is found at the postsynaptic membrane of the 
neuromuscular junction of skeletal muscle in association with cytoplasmic, transmembrane 
anchoring proteins and signalling molecules. A major feature of the neuromuscular junction is 
the presence of a high density of neurotransmitter receptors due in part to myonuclei at the 
synapse selectively transcribing AChR genes, and partly because of the clustering of the 
AChRs (Burden, 1998, Sanes and Lichtman, 1999). A high density of AChRs is critically 
important for transmission of a nerve impulse across the neuromuscular junction. Rapsyn and 
another protein, agrin, activate a muscle-specific kinase (MuSK) and have been shown to be 
essential for AChR clustering at the neuromuscular junction. 
 
Although the tertiary protein structure of rapsyn is unknown, the structural domains of rapsyn 
have been shown to have distinct functions. The primary structure of rapsyn contains a 
consensus sequence for N-myristoylation. Fatty acid modification of the N-terminus has been 
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shown to enable rapsyn to be localised to the plasma membrane. In addition the 10 amino 
acids at the N-terminus are conserved across the species, suggesting this region may be 
important in protein interactions. Rapsyn contains 7 tetratricopeptide repeats (TPRs) (Figure 
22). These are 34-amino acid alpha helical repeats believed to be involved in protein-protein 
interactions. A minimum of two TPRs are required for self-association to take place. Self-
association of rapsyn enables the AChR to be linked to the cytoskeleton (Ramarao and Cohen, 
1998). 
 
The coiled-coil rapsyn domain is required for AChR clustering and rapsyn binds the long 
cytoplasmic loop of the AChR through the coiled-coil domain (Huebsch and Maimone, 2003).  
Cytoplasmic AChR domains are positioned close to rapsyn (Burden, 1998). Clustering of the 
AChRs appears to occur through the interaction of the coiled-coil domain with the 
cytoplasmic loop of either the beta subunit of the AChR (Bartoli et al., 2001), the alpha 
subunit of the AChR (Maimone and Enigk, 1999) or the delta subunit of the AChR (Muller et 
al., 2006). The Ring-H2 domain at the cysteine-rich COOH-terminus of rapsyn has not been 
shown to be necessary for rapsyn self-association or AChR clustering. However, the Ring-H2 
domain interacts with the cytoplasmic tail of beta-dystroglycan resulting in dystroglycan 
clustering, providing a link between the extracellular matrix and the cytoskeleton. This is 
believed to be important in the organisation of the post synaptic membrane (Bartoli et al., 
2001, Cartaud et al., 1998). The ability of rapsyn to cluster dystrophin in the absence of 
AChRs suggests it may stabilize AChR clustering by connecting the receptors to the 
cytoskeleton anchored dystrophin-glycoprotein complex at the neuromuscular junction (Lin et 
al., 2001). Agrin also plays an important role in maintaining the postsynaptic architecture 
(Apel et al., 1995). The amino acid 361-412 motif is found in other transcription factors 
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localised to the nucleus. It has been suggested that in the absence of a membrane-targeting 
signal, interaction with other nuclear associated proteins may localise it to the nucleus. It has 
also been suggested that this domain may have a role in determining the size of the AChR-
rapsyn clusters (Ramarao et al., 2001). 
 
1177delAA mutation 
 
 
 
Figure 22: The structure of rapsyn illustrating the position of the c.1177delAA mutation. 
Schematic diagram adapted from Ramarao et al., 2001. 
 
The importance of rapsyn and a muscle-specific kinase (MuSK) for the initiation of 
postsynaptic differentiation has been demonstrated in transgenic mice. In mouse models, 
transgenic mice with targeted disruption of the rapsyn gene maintained synapse specific 
transcription of AChR genes. However, no detectable AChR clusters were seen, indicating 
rapsyn was essential for AChR aggregation at the neuromuscular junction. These mice had 
muscle weakness, severe respiratory distress, and died within hours after birth (Gautam et al., 
1995). 
 
Genotype-phenotype correlations have been described for CMS-associated RAPSN mutations, 
such that individuals who are homozygous for the most frequent RAPSN mutation (p.N88K 
missense mutation) associated with CMS (Muller et al., 2003) have less severe disease than 
compound heterozygotes with a single p.N88K allele (Dunne and Maselli, 2003). Previously 
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it was reported that the rapsyn missense mutation p.N88K showed a partial loss of function 
with reduced, less stable agrin-induced AChR clusters than wild type rapsyn (Cossins et al., 
2006). Thus p.N88K may cause a less severe defect than mutations that produce a truncated 
protein or altered membrane attachment.  Homozygosity (or compound heterozygosity) for 
RAPSN mutations predicted to cause a truncated protein have not been described in CMS to 
date. The c.1177_1178delAA mutation identified in our family has not been observed in 
samples from 340 control chromosomes (140 in the current study and 200 reported 
previously). It has previously been reported (in combination with the p.N88K allele) in 
patients with CMS (Burke et al., 2003). Affected patients had decreased fetal movements, 
flexion contractures, craniofacial anomalies, hypotonia and intermittent respiratory failure 
(Burke et al., 2003, Banwell et al., 2004).  The c.1177_1178delAA frameshift mutation was 
predicted to abort the stop codon at residue 392 in the Ring-H2 domain extending the protein 
by 62 C-terminal missense amino acids. It was anticipated that the larger rapsyn molecule 
may be sequestered in the endoplasmic reticulum during protein trafficking or that the altered 
protein structure may impair interaction with other proteins resulting in reduced AChRs at the 
neuromuscular junction. Thus it was suspected that the c.1177_1178delAA mutation caused a 
more severe deficit in rapsyn function than p.N88K and so homozygosity for 
c.1177_1178delAA caused a fetal akinesia rather than a CMS phenotype. This was supported 
by the studies of the c.1177_1178delAA mutation on rapsyn function undertaken by Professor 
Beeson’s team, which showed that homozygosity for this frameshift RAPSN mutation 
severely impaired protein stability (Vogt et al., 2008).  
 
Thus RAPSN mutations may cause a spectrum of phenotypes ranging from later onset (third 
decade) CMS with “mild mutations” through neonatal CMS with arthrogryposis, to fetal 
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akinesia with lethality in the presence of homozygous severe truncating mutations (Burke et 
al., 2004) . Although the development of neuromuscular junction differs in mice and humans 
(in mice the switch from fetal to adult acetylcholine receptors takes place in the first two 
weeks of life, but in humans the switch occurs earlier and is apparently complete by 31 weeks 
gestation), (Kues et al., 1995, Hesselmans et al., 1993), the phenotype of Chrng and Rapsn 
gene inactivation in mice are similar. Homozygous mutant transgenic mice with targeted 
disruption of the rapsyn gene died within hours of birth with respiratory insufficiency and 
profound muscle weakness (Gautam et al., 1995). These mice showed no detectable AChR 
clusters along the length of muscle fibres. When these findings are considered together with 
CHRNG mutations, functional AChR deficiency will be a significant cause of MPS/fetal 
akinesia (Morgan et al., 2006, Hoffmann et al., 2006). 
 
Although germline mutations in CHRNA1, CHRNB1 and CHRND were not identified in our 
cohort of patients, mutations in CHRNA1 and CHRND have been identified in MPS patients 
(Michalk et al., 2008), supporting the role of the various AChR genes in disorders of the 
neuromuscular junction (NMJ). 
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Chapter 6: Candidate Gene Analysis DOK7  
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6 Candidate Gene Analysis DOK7  
 
A substantial part of this chapter has been published in Vogt et al., 2009.  
 
6.1 Introduction 
 
Germline mutations in CHRNG, encoding the fetal gamma subunit of the acetylcholine 
receptor (AChR) have been reported to account for ~30% of lethal and non-lethal (Escobar 
variant) multiple pterygium syndrome (LMPS and EVMPS) (Morgan et al., 2006, Michalk et 
al., 2008, Hoffmann et al., 2006). Subsequently mutations in genes that encode other fetal 
AChR subunits (CHRNA1, CHRND) or the crucial AChR clustering protein rapsyn (RAPSN) 
have been detected in FADS/LMPS (Vogt et al., 2008, Michalk et al., 2008). Mutations in 
CHRNA1, CHRND, and RAPSN have also been described in congenital myasthenia syndrome 
(CMS), a disorder that is characterised by muscle fatigability and, rarely, arthrogryposis 
(Brownlow et al., 2001, Burke et al., 2003, Beeson et al., 2005). Thus it was hypothesised that 
mutations in DOK7, a gene that has been implicated in CMS and fetal AChR function (Selcen 
et al., 2008), might also cause a FADS/LMPS phenotype.  
6.2 Results  
 
Fourteen families with features of FADS/LMPS (see Table 9) and no evidence of CHRNG, 
CHRNA1, CHRNB1, CHRND and RAPSN mutations were examined for germline mutations 
in the exons and flanking intronic sequences of DOK7 by direct sequencing on an ABI 3730 
DNA Analyser. 
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Family ID 
Ethnic 
Origin 
Parental 
Consanguinity Phenotype 
MPS012 Bengali  Yes No pterygia 
MPS013 Pakistani Yes LMPS 
MPS016 White No LMPS 
MPS017 White No LMPS 
MPS019 Indian  No LMPS 
MPS020 White  No LMPS 
MPS021 White Yes LMPS 
MPS022 Afrikaner No LMPS 
MPS023 White  No LMPS 
MPS027 Afrikaner No LMPS 
MPS028 
Afro 
Caribbean No LMPS 
MPS010 Pakistani Yes No pterygia 
MPS009 Pakistani Yes LMPS 
MPS029 Turkish Yes LMPS 
   
 
 
 
   
    
 
   
Table 9: 14 families with FADS/LMPS. 
These patients had no evidence of CHRNG, CHRNA1, CHRNB1, CHRND and RAPSN mutations and were 
examined for germline mutations in the exons and flanking intronic sequences of DOK.  
 
A homozygous DOK7 splice site mutation (c.331+1G>T) was identified in a consanguineous 
Bengali family with three children affected with the fetal akinesia deformation sequence 
(Figure 23). Both parents and the two unaffected siblings were heterozygous for the mutation. 
The mutation was not detected in 378 ethnically matched control chromosomes. Because this 
nucleotide substitution affects the consensus donor splice site motif, it is likely to abolish 
correct RNA splicing and an in silico splice site prediction programme 
(http://www.fruitfly.org/seq_tools/splice.html) suggested that the consensus donor splice site 
was lost in the mutant sequence.  It was not possible to directly examine the effect of the 
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mutation on RNA splicing. This is because there was no fetal tissue available from which 
RNA could be extracted and I was unable to detect DOK7 expression on the cDNA PCR 
studies undertaken on blood. However, this mutation was predicted to result in exon 3 
skipping of an in frame deletion of 77 amino acids from the PH domain of DOK7. This in 
frame skipping of exon 3 has previously been confirmed and it had been shown that Dok-7 
harbouring this mutation impairs MuSK activation in cultured cells (Selcen et al., 2008). 
 
We postulated that the c.331+1G>T mutation caused a severe deficit in Dok-7 function 
resulting in fetal akinesia, rather than a CMS.  
 
 
 
Normal control  Homozygote   Heterozygote 
 
 
 
    
 
 
 
Figure 23: Sequence traces for normal control, homozygote and heterozygote carrier of DOK7 splicesite 
mutation (c.331+1G>T). 
 
7 6 5 4 3 2 1 
c.331+1G>T 
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Review of the clinical records revealed that the first fetus was stillborn at 32 weeks gestation 
and had signs of a neuromuscular developmental abnormality. The second affected fetus 
miscarried spontaneously at 22 weeks of gestation. Post mortem examination revealed that the 
fetus had downslanting palpebral fissures, a small jaw and a short neck. The limbs had 
extended extremities, overlapping fingers, normal palmar creases, bilateral talipes and 
rockerbottom feet with reduced muscle bulk. Bilateral hydrothoraces and severe generalised 
oedema was present. Histopathological examination detected features of a muscle denervation 
type lesion. Thus the muscle appeared immature, with irregularly shaped muscle cells, and 
there was a disparity in the slow to fast muscle density with patchy foci of slow fibres and 
atrophy of the fast fibres, Figure 24 (i) and (ii). The third affected fetus was detected by 
ultrasonography at 24 weeks of gestation when no fetal movements were observed. None of 
the affected fetuses had evidence of pterygia.  
 
(i)   (ii)  
 
Figure 24: (i) and (ii). Immature muscle with irregularly shaped muscle cells. 
There was a disparity in slow to fast muscle fibre density with patchy foci of slow fibres and atrophy of 
fast fibres, considered to be compatible with a neuromuscular disease. 
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6.3 Discussion 
 
DOK7 (Downstream of kinase) is a seven exon gene located on chromosome 4. It encodes a 
55-kD AChR clustering protein comprised of 504 amino acids (Okada et al., 2006). Like the 
other Dok family proteins Dok-7 contains a pleckstrin homology (PH) and phosphotyrosine 
binding (PTB) domain in the N-terminal region and Src homology 2 (SH2) domain target 
motifs in the C-terminal portion (Figure 25).  
 
 
 
 
 
 
 
 
 
Figure 25: Structure of Dok-7 protein. 
 
 
In C2C12 mouse myotubes Dok-7 binds to the MuSK phosphotyrosine binding domain target 
motif through its PTB domain and induces the tyrosine phosphorylation of MuSK, This 
results in numerous differentiated AChR clusters and co-clustering of Dok-7 with the AChR 
(Okada et al. 2006), Figure 26 below.  
c.331+1G>T mutation  Frequent CMS mutations    frequent CMS mutations 
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CCC-terminal domain  N 
Freq ent CMS mutations 
 Frequent CMS mutations    frequent CMS mutations 
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Figure 26: Role of Dok-7 in AChR clustering.  
(Adapted from Palace et al., 2007). 
 
 
Homozygous DOK7 mutations have previously been detected in autosomal recessive 
congenital myasthenic syndrome (CMS) (Beeson et al., 2006, Muller et al., 2007, Palace et 
al., 2007), where they have been associated with small neuromuscular junctions, reduced 
postsynaptic folding but normal AChR density and function (Slater et al., 2006). Patients with 
DOK7 mutations, almost always have at least one allele with a mutation, commonly the 
frameshift mutation 1124_1127dupTGCC, in exon 7 of the C-terminal region.  CMS 
compound heterozygotes with the recurrent exon 7 mutation and a N-terminal mutation either 
in the PH or PTB domain have infrequently reported with early childhood onset limb girdle 
CMS  (Palace et al., 2007). However severe homozygous or compound heterozygous 
mutations in the PH region of DOK7 have not been described in CMS. Truncating mutations 
in the C terminal domain of Dok-7 result in an impaired ability to induce the phosphorylation 
of MuSK and to form the specialization of the postsynaptic structures (Beeson et al., 2006). 
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CMS patients homozygous for these mutations do not usually present at birth but in early 
childhood. This may suggest that there is little effect on initial synapse formation but 
impaired maturation and maintenance of synaptic structures (Beeson et al., 2006). 
 
Although variable in severity, CMS patients with DOK7 mutations typically have a limb 
girdle pattern of muscle weakness with the muscles of the limbs and trunk mainly affected. 
Facial and bulbar weakness is frequent, ptosis is common and eye movements are usually 
unaffected. Although respiratory impairment may be present from early life, DOK7 mutations 
are more frequently associated with progressive respiratory deterioration over time 
necessitating nocturnal ventilation. Congenital joint contractures seen in CMS patients with 
RAPSN mutations are not a feature of DOK7-associated CMS (Palace et al, 2008).  
The severe homozygous intron 3 splice site mutation in the PH domain was lethal in uterine 
life in the affected fetuses. This may suggest an effect on early synaptic development and 
severe disruption of Dok -7 function. It is possible that the mutation in the PH region may 
interfere with the docking of other signal transducing molecules or other neuromuscular 
junction proteins in the neuromuscular junction. Although the development of neuromuscular 
junction differs in mice and humans, the phenotype of Chrng, Rapsn and Dok7 knockout mice 
are similar. Thus Dok7 deficient mice were unable to breathe or move and died shortly after 
birth, suggesting a severe neuromuscular transmission defect, whereas their heterozygous 
littermates appeared normal. The Dok7 deficient mice had no detectable AChR clusters in the 
endplate region of the diaphragmatic muscle, consistent with Dok-7 having a critical role in 
neuromuscular synaptogenesis (Ohno et al., 2002). This is consistent with the hypothesis that 
incomplete loss of Dok-7 function causes a CMS phenotype whereas complete loss of 
function is lethal.  
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The identification of germline mutations in various AChR neuromuscular junction (NMJ) 
genes supports their role in the aetiology in MPS / FADS. Mutations in genes only expressed 
in fetal life result in a severe in utero phenotype of LMPS or FADS whereas mutations 
occurring in genes expressed late in gestation or postnatally cause a postnatal onset CMS. 
Mutations in genes expressed throughout pre and postnatal life can cause both MPS / FADS 
and CMS as summarised in Table 10 below. 
 
 
Table 10: Phenotypic variability and allelic heterogeneity in inherited NMJ disease. 
 
Based on the current understanding of the underlying molecular pathology, a molecular 
genetic diagnostic pathway was designed for the investigation of MPS/FADS. It was 
proposed that CHRNG mutation analysis should be offered to families with likely autosomal 
recessive EVMPS, as the detection rate was estimated to be in the order of one quarter. In the 
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LMPS/FADS families where central nervous system malformations were present, the 
detection rate for the acetylcholine receptor pathway genes was considered likely to be low, 
and therefore an alternative pathology should be considered. For LMPS/FADS patients with 
pterygia, CHRNG mutation analysis would be recommended followed by CHRNA1 and 
CHRND if negative. In the absence of pterygia, RAPSN and DOK7 mutation analysis may be 
pursued before CHRNG, CHRNA1 and CHRND (Figure 27).   
FADS/LMPS molecular data 
FADS/LMPS (24%)
8% 
(1-14%)
CHRNG 
mutations
pterygia
3% 
(0-8%)
CHRNA1 
mutations
pterygia
3% 
(0-8%)
CHRND 
mutations
pterygia
3% 
(0-6%)
RAPSN 
mutations
No 
pterygia
7% 
(0-20%)
DOK7 
mutations
No 
pterygia
 
Figure 27: Molecular Genetic Data for LMPS / FADS. 
This figure shows the relative contribution of mutations in the AChR genes and denotes the presence or 
absence of pterygia. Note the wide confidence intervals due to small number of data points in some cases, 
(Vogt et al., 2012). 
 
The FADS/LMPS mutation detection rate for each individual gene is not high however this is 
likely to improve with the identification of other molecular causes of these conditions in the 
future. 
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7 Mapping new genes 
7.1 Introduction 
 
In the multiple pterygium syndrome (MPS) / fetal akinesia deformation sequence (FADS) 
cohort there were many families for which the underlying molecular cause had not been 
elucidated despite screening for mutations in the known candidate genes.  Families were 
assessed for their suitability for other gene mapping techniques. Families selected for possible 
further study included those with a well-defined phenotype, a history of consanguinity, 
multiple affected relatives including cousins rather than solely within sibships and availability 
of DNA samples from the affected individuals as well as other family members. The family 
below was selected for further study: 
11
3334 3 4 4 5 3 4
 
   II.5         II.1  II.2   II.3   II.4 
                               Family branch b          Family branch a 
  
Figure 28: Affected children in two branches of a consanguineous family. 
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7.1.1 Clinical Details 
 
The consanguineous Pakistani family above (Figure 28) was referred by Dr Geoff Woods, for 
autozygosity mapping work. There were three affected pregnancies in two branches of the 
family. All the affected children had a similar phenotype with reduced fetal movements 
evident by 20 weeks of pregnancy, bilateral fixed talipes and fixed flexion of the arms across 
the chest. At birth they had severe multiple contractures with pterygia of the knees and 
elbows. All the affected children that had been examined had a small u-shaped midline cleft 
palate and renal pelviceal dilatation. One of the children that survived for several months had 
urinary reflux and recurrent urinary infections. This child was physically delayed and had 
severe intellectual disability. Microcephaly was a feature however intracranial imaging was 
normal. 
 
Family branch a 
 
First pregnancy was a healthy son. The second pregnancy was an affected female with 
congenital arthrogryposis, pterygia of the elbows and knees, a cleft palate and renal pelvic 
dilatation. The third pregnancy was interrupted because it was affected. The fourth pregnancy 
was an affected female born with severe congenital arthrogryposis, multiple pterygia, a cleft 
palate and renal pelvic dilatation. She had severe developmental delay and was not very 
responsive. 
 
The family later went on to have a fifth pregnancy in which there was polyhydramnios and a 
reduced βHCG level. There was increased nuchal translucency, bilateral flexion contractures 
at the elbows but more arm movements than in previous pregnancies. The affected female was 
born post term with a birth weight of 7lb. She was stable in the neonatal period and could 
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bottle feed in the first year. However, she developed recurrent chest infections and was 
diagnosed with gastroesophageal reflux and aspiration pneumonia. She underwent a Nissen 
fundoplication and an insertion of a gastrostomy feeding tube. She has been gaining weight. 
She has had no seizures but frequent jittery episodes. Developmentally she smiles 
occasionally. She cannot focus but is reactive to bright light and there is some response to 
loud sounds. Her muscle strength appeared to be improving and she can move all four limbs 
spontaneously. 
 
At the age of 2½ years her weight was above the 75 percentile and she had severe 
microcephaly. Her tone was reduced and she had generalised oedema, particularly affecting 
the feet. She had mild hypotelorism, large low set posteriorly rotated ears, micrognathia and a 
cleft palate. She had a short neck with a pterygium between her mandible and chest, elbow 
pterygia and a mild popliteal pterygium on the left. She had widely spaced nipples and a 
normal cardiac examination. She had clenched hands with short tapering fingers and bilateral 
single palmar creases. She had short toes with mild syndactyly between toes 2 and 3 on the 
left. 
 
A postnatal echo was normal. A micturating cystogram showed a markedly distended 
neuropathic bladder that with a significant second bladder wall, trabeculations and multiple 
diverticulae. The patient had suspected cortical visual impairment with a normal 
ophthalmology examination. A hearing test was normal. A skeletal survey showed 11 pairs of 
ribs. Acetylcholine receptor antibodies were negative and her karyotype was 46,XX.  
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A mutation was not identified in CHRNG however the presence of a heterozygous single 
nucleotide polymorphism (SNP) in this gene was noted. RAPSN was also screened and no 
mutation was identified. Heterozygous SNPs were observed in CHRNA1 and CHRNB1. 
There are no further clinical details currently available on the family. 
 
Family branch b 
 
This branch of the family had a single similarly affected deceased male child. There was little 
clinical information about this pregnancy. 
 
7.2 Results 
 
Autozygosity mapping techniques were utilized to investigate novel candidate genes for 
MPS/fetal akinesia in this consanguineous family. A 10cM genome wide linkage scan was 
undertaken using the Affymetrix 500K SNP Array to genotype three affected children (2 
siblings and 1 cousin), II.3, II.4 and II.5 from the two branches of the family with similarly 
affected children. Four regions of homozygosity were identified in the three affected patients. 
However, only one of these regions extended to four megabases (Figure 29). This was a 
region on chromosome 3 between rs161661 and rs9814327; bp position g.60,958,320- 
g.64,091,416; hg18, NCBI 36.3. As it has been shown previously that regions of this 
magnitude have a one in six chance of containing the causative candidate gene, this region 
was targeted for fine mapping (Woods et al., 2006).  
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Figure 29: Affymetrix 500K SNP Array: 4Mb region of homozygosity extending from 60958320 bp to 
64091416 bp, seen on analysis of the DNA from the 3 affected children II.3, II.4 and II.5. 
 
Fluorescently labelled microsatellite markers were chosen at 0.5-1Mb intervals along the 
length of this region. From the results of the analysis, linkage to this region could not be 
excluded (Figure 30 below).  
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Marker Physical position (Mb)
D3S1300 60484947 8 8 1 1 11
D3S1239 62034808 2 1 2 2 2 2 2
D3S1312 62381450 3 9 3 9 3 3 17
D3S3566 62517684 4 10 4 1 4 4 1
D3S3698 63094825 5 11 5 11
D3S1600 63295167 6 12 6 12 6 6 18
D3S1285 64914199 7 13 7 16 7 13
D3S1300 60484947 8 1
D3S1239 62034808 2 2 2 2 2 2
D3S1312 62381450 3 3 3 3 3 3
D3S3566 62517684 4 4 4 4 4 4
D3S3698 63094825 5 5 5 5
D3S1600 63295167 6 6 6 6 6 6
D3S1285 64914199 7 7 7 7 7 13
II: 1 II: 2 II: 3 II: 4 II:5
I:1 I:2 I:4I:3
inferred
 
Figure 30: Fine mapping of region of homozygosity in family branches a and b. 
 
 
7.2.1 Candidate Genes  
 
The known genes located in the region were assessed (see table 11 below). The following four 
genes were considered to be promising candidate genes and were therefore prioritised for 
sequencing in the first instance in this family:  
 
SYNPR 
 
Synaptoporin is a five exon gene with two splice variants. It belongs to the synaptophysin 
family and is a membrane protein integral to synaptic vesicles. It has 97% homology with rat 
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synaptoporin and 81% homology with that of the chicken (Dai et al., 2003). It has been shown 
to be differentially expressed in the dorsal root ganglia of the rat. It was expressed in just over 
half of a subset of small neurones. In the spinal cord, rat synaptoporin is strongly expressed in 
the afferent fibres in laminae III and IV and weakly present in the other layers. Upregulation 
of synaptoporin occurs following peripheral nerve injury. It was deduced to be a major 
synaptic vesicle protein in A and C fibres in physiological and neuropathic pain (Sun et al., 
2006). Human synaptoporin is specifically expressed in brain tissue (Dai et al., 2003). 
 
FEZF2 
 
FEZ family zinc finger 2 is a five exon gene. The 503 amino acid protein product contains six 
highly conserved zinc fingers at the C terminus (Matsuo-Takasaki et al., 2000). In mice it is 
not expressed in muscle but is selectively expressed by the pyramidal neurones in layers V 
and VI of the brain. Decreased FEZ2 expression reduced and altered the morphology of the 
subcortical axonal projections of the pyramidal neurones whereas misexpression resulted in 
ectopic subcortical axonal projections. In null mice the corticospinal tracts and Ctip2 the 
transcription factor for formation of these tracts was not expressed. Thus FEZ2 was shown to 
regulate differentiation on the fifth layer subcortical projection neurones and therefore to have 
an important role in the differentiation of subcortical projection neurones (Chen et al., 2005, 
Chen et al., 2008). There were no subcerebral projections and no cortical projections into the 
brain stem and spinal cord in null mice and no other neuronal cells were affected (Molyneaux 
et al., 2005).  
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PRICKLE2 
 
This gene is located on chromosome 3p14. It is an eight exon gene comprised of 844 amino 
acids. It contains an N-terminal PET domain, three LIM domains and a prickle homology 
domain at the C-terminus. PRICKLE2 is 50% homologous with PRICKLE1 with 80% 
homology in the N-terminal PET and LIM domains. PRICKLE2 and PRICKLE1 are 
coexpressed in the brain, the eye and the testis. PRICKLE2 is also expressed in the fetal brain, 
adult cartilage, pancreatic islet cells, gastric cancer and uterine tumour cells (Katoh, 2003).  
Heterozygous missense mutations in PRICKLE2 have been identified siblings with 
progressive myoclonic epilepsy and unrelated patients with myoclonic seizures. It has been 
suggested that PRICKLE2 has a role in the development of a neural network through its effect 
on cell polarity or affects calcium signalling providing an alternative mechanism for the 
seizure condition. In the animal model, heterozygous prickle1 and prickle2 null mice had a 
susceptibility to seizures.  
 
ATXN7 
 
The ATXN7 gene maps to chromosome 3p14.1. It has thirteen exons ranging from 69 to 979 
bp in size with the CAG repeat located in exon 3. The introns vary in size from 233 bp to 
about 40 kb, so that the overall size of ATXN7  is about 140 kb (Michalik et al., 1999). 
ATXN7 is a transcription factor that appears to have an important role in histone acetylation 
for chromatin remodeling and deubiquitination (Sopher et al., 2011). Heterozygous CAG 
triplet repeat expansions of this gene are associated with spinocerebellar ataxia type 7 
(SCA7). Patients with SCA7 have highly unstable and variable CAG repeats ranging from 38 
to 130, compared with 7 to 17 repeats on control alleles (David et al., 1997). However, 
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diseases states have not been reported in association with homozygous frameshift or nonsense 
mutations in this gene.  
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BLAST The Human Genome  
Genes On Sequence All Sequence Maps   next 
 
Total Genes On Chromosome: 1638 [8 not localized]   Region Displayed: 60,960K-64,090K bp Genes in Region: 18    
 
 start stop Symbol  Description 
 59710076 61212164 FHIT       fragile histidine triad gene 
 61522285 62254738 PTPRG       protein tyrosine phosphatase, receptor type, G 
 61703110 61718860 LOC100128936       similar to ribosomal protein L10a 
 62084054 62085426 ID2B       inhibitor of DNA binding 2B, dominant negative helix-loop-helix protein 
 62280436 62294361 C3orf14       chromosome 3 open reading frame 14 
 62330387 62334230 FEZF2       FEZ family zinc finger 2 
 62359061 62836094 CADPS       Ca2+-dependent secretion activator 
 62886941 62887626 LOC389127       similar to 40S ribosomal protein S10 
 63057090 63162129 LOC132205       similar to tau tubulin kinase 2 
 63163934 63164164 LOC100129031       hypothetical LOC100129031 
 63404064 63577637 SYNPR       synaptoporin 
 63613384 63625933 FLJ44379       similar to S-100 protein, alpha chain 
 63713311 63773851 LOC100130345       hypothetical protein LOC100130345 
 63775826 63809352 C3orf49       chromosome 3 open reading frame 49 
 63794586 63824637 THOC7       THO complex 7 homolog (Drosophila) 
 63825273 63961367 ATXN7            ataxin 7 
 63971271 63984160 PSMD6                  proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 
 64054587 64186171 PRICKLE2  
             prickle homolog 2 (Drosophila) 
 
Table 1: NCBI Map ViewHomo sapiens (human)Build 36.3 (Current). 
Candidate genes PRICKLE2, ATXN7, SYNPR, CADPS and FEZF2 were selected for from the region of interest. Sequencing of these genes was undertaken on affected child and 
parent pairs. No pathological mutations were identified in these genes. 
134 
Sanger sequencing was undertaken on these genes however a pathogenic mutation was not 
identified in this family. 
 
Exome sequencing was undertaken in this family on DNA from a single affected female 
proband II.4. It was predicted that homozygous mutations would be detected in the affected 
patients. Data from the genome wide linkage was used to focus the analysis to the largest 
regions of homozygosity already identified. A total of 28,384 sequence variants were 
identified. 204 were classified as homozygous and novel. Of these 5 were nonsense variants, 
185 were missense and 14 were splicesite. 95 were located on chromosome 3 however only 
none of these variants were located in the candidate region. Within this region there was only 
a single homozygous intronic variant in PRICKLE2. 
 
Work done by HP Vogt, 2010 using autozygosity mapper established two further regions of 
homozygosity: a region on chromosome 7 of approximately 3 megabases extending from 
2,999,096 base pairs to 5,853,557; and a 2 megabase region extending from 122,803,491 to 
124,735,879 on chromosome 12. On further interrogation of the WES data a single 
homozygous novel exon 5 A>G splicesite variant was detected in position 4181929 within the 
region of interest on chromosome 7. 
 
The variant identified was in a gene called SDK1, sidekick of drososphila, homolog of, 1 
(OMIM number 607216). SDK1 and SDK2 are homologous transmembrane molecules 
belonging to the immunolglobulin superfamily. The signal sequence is comprised of 6 
immunoglobulin C2 motifs, 13 fibronectin type III motifs, a single transmembrane domain 
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and a 200 amino acid cytoplasmic domain. There is a conserved C-terminal hexapeptide 
sequence GFSSFV in all SDKs. The SDK proteins are believed to be evolutionary conserved 
in size and structure in species ranging from C.elegans through to Drosophila and vertebrates. 
SDKs are concentrated in synaptic regions where pre and post synaptic SDK expressing cells 
connect.  In vitro studies in retinal cells have shown that ectoptic production of SDK redirects 
cell processes. It is therefore plausible that SDKs are important target recognition molecules 
in synaptogenesis that can influence cell connectivity (Yamagata et al., 2002). SDKs 1 and 2 
been shown to have a role in cell adhesion between neurones and are believed influence 
specific connectivity in the eye and also other parts of the central nervous system (Yamagata 
and Sanes, 2008). It is thus conceivable that biallelic mutations in SDK1 may be detrimental 
to development of the central nervous system and could result in a fetal akinesia phenotype, 
due to impaired brain development, as noted in our family. 
 
Unfortunately I was unable to undertake further laboratory work on SDK1 as my research 
attachment was completed. However the variant detected in SDK1 appears to be a good 
candidate gene that may warrant further investigation including confirmation with 
conventional Sanger sequencing, segregation studies, analysis of ethnically matched 
controlled chromosomes, and SDK1 sequencing of the fetal akinesia cohort for other affecteds 
with homozygous or compound heterozygous SDK1 sequencing variants. Future functional 
studies may be helpful for validation.  Splice sites are at the junction of intron and exons. The 
5’ (splice donor site) and 3’ (splice acceptor site) ends have recognisable consensus sequence 
for mRNA. The splice donor site is AG and at the splice acceptor site is GT in 98.71% of 
mammalian genes (Burset et al., 2000). The homozygous splice variant A>G detected may 
therefore be significant. Overall, no definite causative pathogenic mutations were detected in 
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this family. In the future further analysis in planned. In addition, regions not well covered by 
the exome sequencing can be studied in more detail and other regions of homozygosity 
explored. 
 
7.3 Discussion 
 
Due to the phenotypic and molecular genetic heterogeneity and the diverse 
mechanisms of disease that are evident in MPS/FADS, various genetic strategies have 
been employed for gene identification. In addition to screening a large cohort of 
patients for mutations in CHRNG, which was previously identified as a significant 
cause of lethal and nonlethal MPS, a candidate gene approach which included testing 
of other neuromuscular junction pathway genes was also done.  Consanguineous 
families without an identifiable mutation in a known gene were scrutinised to see if 
they would be suitable for an autozygosity mapping approach. This could potentially 
result in identification of a novel cause of FADS / MPS and provide further insights 
into other mechanisms of disease. The family above was selected for further study. 
 
Despite employing a combined approach of SNP arrays to localise large regions of 
homozygosity likely to harbour the disease gene, analysis of suitable candidate genes 
and next generation technology using exome sequencing, the causative pathogenic 
gene was not identified in this family. There are a variety of possible reasons why this 
may have been the case. These can be divided into technical and human factors. The 
technical reasons may include poor coverage of the regions of interest and an inability 
to examine non coding sequences. The gene of interest may also in a minority of cases 
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lie within small regions of homozygosity (<4Mb).  Human error in the clinical 
interpretation of phenotypic features and failure to recognise significant data are other 
possibilities. Certainly exome sequencing of more than one affected individual in the 
family may have increased the power of this technique and reduced errors or oversight 
due to both technical and human factors. With the advancement in next generation 
sequencing technology and bioinformatics support many of these difficulties may be 
minimised and more successful gene discovery expected.  
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8: Discussion 
 
 
This project was designed to investigate the clinical and molecular genetics of the 
multiple pterygium syndromes (MPS), as up until the time of this research study our 
understanding of the underlying genetic causes of this group of conditions and the 
phenotypic correlations has been limited. 
 
From the previous studies of families with clinical features of MPS it is recognised 
that the non-lethal Escobar variant of the condition as well as lethal MPS is usually 
inherited in an autosomal recessive fashion. Mutations in the fetally expressed gamma 
subunit of the acetylcholine receptor encoded by CHRNG have been identified as a 
significant cause of Escobar and lethal MPS, accounting for approximately a third of a 
small group of families tested. In the initial phase of the study my patient cohort 
comprising 100 families was sequenced in order to determine the frequency of 
CHRNG mutations in the largest group of MPS/FADS patients to date. This analysis 
confirmed that CHRNG mutations were the significant cause of MPS / FADS. In this 
large cohort study CHRNG mutations were detected in 27% of the Escobar variant 
patients and in 8% of lethal LMPS / FADS families. This was a slightly lower 
CHRNG mutation detection frequency than that in the original gene identification 
reports. This may have been because the previous studies were undertaken on a small 
sample size of highly selected predominantly consanguineous patients with very 
similar phenotypic features. Thus the detection rate in our large patient cohort is more 
likely to reflect the overall detection rate of CHRNG mutations in a wider spectrum of 
patients.  
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A genotype phenotype study was undertaken to investigate the correlation between 
the clinical features present in the affected patients and the molecular findings in this 
cohort. When the clinical features were analysed, the presence of pterygia was 
associated with detection of a CHRNG mutation. CHRNG encodes the fetally 
expressed gamma subunit of the acetylcholine receptor, critical for in utero 
transmission of nerve impulses across the neuromuscular junction and consequently 
for fetal movement. Thus the severe, early onset fetal akinesia caused by mutations in 
the embryonal acetylcholine receptor may provide a mechanism for development of 
pterygia. The development of joint contractures without webbing may instead be due 
to partial or later onset fetal immobility, hypokinesia rather than akinesia or inhibition 
of fetal movement later in gestation possibly due to different underlying molecular 
mechanisms. Fetal hydrops was also a poor prognostic sign in keeping with severe 
immobility early in gestation and indicating a severe manifestation of the condition. It 
is also possible that included within this cohort were fetuses with unrecognised 
congenital cardiac malformations either as a component of the LMPS or as part of 
another unrecognised syndromic condition which may have have contributed to the 
poor prognosis in the hydropic group. 
 
Central nervous system malformations can cause reduced or abnormal fetal 
movements however central nervous system malformations were not associated with 
the presence of a CHRNG mutation. The MPS / FADS are phenotypically and 
genetically heterogeneous and thus abnormal intracranial development is likely to 
indicate a different pathology and an alternative molecular or other mechanism may 
need to be sought.  The presence of a cleft palate was not highly associated with the 
detection of a CHRNG mutation. This may be because although a high or cleft palate 
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may occur as a result of the fetal akinesia sequence, an alternative mechanism or 
different molecular pathology may underlie the clefting process in some patients. 
Identification of in-utero features of fetal akinesia correlated with lethality, 
particularly in the absence of a family history of this condition. This is likely to be a 
reflection of the severity of the phenotype and thus its detection. 
 
This study also examined the distribution of CHRNG mutations across the gene and 
the associated clinical phenotype to see if there was a correlation between particular 
developmental features and specific mutations. It was anticipated that this may enable 
the phenotype to be predicted from the CHRNG mutation and this in turn would 
provide information about the biological role of various CHRNG domains.  However 
CHRNG mutations were detected throughout the gene and neither the position nor the 
character of the mutation appeared to correlate with the severity of the phenotype. 
Interfamilial variation and intrafamilial phenotypic variation was noted in the cohort 
with the same CHRNG mutation for example the recurrent c.459 dupA mutation was 
identified in patients affected with a non lethal Escobar phenotype as well as in 
lethally affected fetuses. This indicates that genetic modifiers or compensatory 
mechanisms as well as environmental factors may be important in determining the 
degree of in utero akinesia, the phenotypic consequences of these mutations and the 
prognosis for the patient. This opens up the possibility of future developments that 
could convert a severe phenotype into a milder condition through modulation of other 
genes in the fetus or the local environment.  
 
Although local uterine environmental factors such as physical constraints resulting in 
the fetal akinesia sequence are well recognised, other physiological or therapeutic 
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factors in pregnancy may enhance fetal movement. For example there is a suggestion 
that caffeine based products increase fetal activity (Devoe et al., 1993). There is 
currently no evidence to suggest that fetal movement in early pregnancy is increased 
or this has an effect on ameliorating the phenotype. The use of such products is not 
currently recommended and will need to be evidence based, as the potential benefits 
have to be balanced against the adverse effects, for example fetal growth restriction 
with the consumption of caffeine in pregnancy (CARE Study Group, (2008). 
Importantly the observation that there is apparently less phenotypic variability 
between affected siblings than between affected relatives in the wider family may be 
of practical help in the genetic counselling of MPS / FADS families.   
 
The genotype phenotype study utilized a clinical features questionnaire comprising 
prenatal, antenatal and postnatal questions based on a review of the current literature 
with the input of others working in the field. This therefore had the potential 
disadvantage of focussing the questions and information collected around already 
recognised associated clinical features. In addition, although the largely “yes” “no” 
format was designed for ease of completion to ensure that as many responses as 
possible were obtained, this may have affected the quality of the information supplied. 
In order to encourage the reporting of other possibly interesting or unusual findings, 
opportunities for “other” comments was incorporated into the structure however the 
information provided may have been limited. In addition, due to the sensitivity factors 
related to the nature of the conditions studied, recruitment of affected patients was not 
systematic or complete, but was dependent on referral from the local clinicians if 
appropriate.  Nevetheless, despite these limitations, this study enabled important 
clinical correlations to be established on a large MPS / FADS patient cohort. 
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An initiative from this study has been the development of shared Locus-Specific 
databases (LSDB). The CHRNG sequence variant data has been incorporated onto this 
open access database along with other published data. This will enable the cumulative 
CHRNG sequence variant information and the associated clinical features to be shared 
with others. This database will continue to be populated with information from our 
laboratory and others undertaking CHRNG analysis. It is anticipated that this web-
based resource will provide a more complete picture of the spectrum of CHRNG 
variants detected and the associated phenotypes, which may in turn enhance our 
understanding of the biological properties of the protein encoded genetic regions. This 
is particularly helpful for the CHRNG gene which is fetally expressed making study of 
the sequence variants to establish pathogenicity impractical in most situations.  Thus 
the LSDB will provide an invaluable resource that can be utilised by clinicians and 
researchers in this field.   
 
As MPS / FADs patients are recognised as being phenotypically and genetically 
heterogeneous, further research work was undertaken to try and identify other 
molecular causes of MPS / FADS. A candidate gene approach was adopted and AChR 
pathway genes were selected for sequencing in this condition. In particular genes 
encoding neuromuscular junction components expressed in fetal life were considered 
as plausible candidates, as they would be predicted to cause early onset, severe fetal 
akinesia. The genes encoding the AChR subunits expressed in fetal and postnatal life, 
CHRNA1, CHRNB1 and CHRND were selected. In addition, RAPSN, which encodes 
rapsyn known to be critical for AChR clustering, and DOK7, which has a role in the 
formation of the neuromuscular junction, were also chosen. Homozygous pathogenic 
mutations in RAPSN and DOK7 genes were detected in families with severe lethal 
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fetal akinesia using this strategy. Although germline mutations in CHRNA1, CHRNB1 
and CHRND were not identified in our cohort of patients, mutations in CHRNA1 and 
CHRND have been identified in other MPS patients (Michalk et al., 2008), supporting 
the role of the various AChR genes in disorders of the neuromuscular junction. It is 
envisaged that mutations in CHRNB1 as well as other AChR-related genes will also 
be detected in this patient group in the future.  
 
Thus mutations in several AChR genes and AChR-related genes have been identified 
in MPS/FADS. Patients affected with another group of conditions the congenital 
myasthenic syndromes (CMS) may also have autosomal recessive mutations in AChR 
pathway genes.  The CMS are disorders of neuromuscular transmission. They are due 
to defects in presynaptic, synaptic and post synaptic neuromuscular junction proteins 
(Engel et al., 2002). The majority of post synaptic CMS syndromes are due to a 
deficiency of AChRs at the muscle endplate due to mutations in CHRNE (Engel et al., 
1996). This gene encodes the epsilon subunit of the AChR. As CHRNE is only 
expressed towards the end of gestation and in postnatal life, mutations in this gene do 
not cause a fetal phenotype. Conversely, the gamma receptor subunit of the AChR is 
not expressed postnatally and therefore CHRNG mutations are not associated with 
postnatal muscle weakness and have not been identified in CMS. 
  
Mutations in other AChR genes can also cause CMS.  Interestingly, mutations in 
RAPSN have been associated with a late onset phenotype as well as an early onset 
presentation evident at birth with arthrogryposis, bulbar dysfunction and respiratory 
difficulties. Patients harbouring one common RAPSN mutation N88K and a second 
severe mutation including 1177del2 may represent this intermediate presentation 
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(Burke et al., 2003). Thus there may be a spectrum of acetylcholine receptor 
mutations with phenotypes ranging from CMS, CMS with arthrogryposis and 
breathing difficulties to severe fetal akinesia.  
 
The acetylcholine receptor pathway genes therefore play a crucial role in the 
development of the neuromuscular junction and in muscle contraction in fetal life. 
Factors interfering with normal NMJ development and maturation have a detrimental 
effect on the execution of movement. The phenotypic consequences of autosomal 
recessive mutations in the AChR-related genes depend on the timing and the severity 
of the neuromuscular junction disturbance. Thus AChR genes may cause a spectrum 
of conditions from lethal MPS/FADS, (Vogt et al., 2008) to postnatal CMS (Beeson et 
al., 2003).  
 
As well as providing insights about the mechanisms of disease, genotype phenotype 
information can be utilized to guide the rationale for genetic testing in families. 
CHRNG, RAPSN and DOK7 mutations have been identified in LMPS/FADS (Morgan 
et al., 2006, Vogt et al., 2008, Vogt et al., 2009). However, unlike CHRNG mutation 
positive patients, in whom pterygia were almost always present, the small number of 
cases identified with RAPSN and DOK7 mutation did not have pterygia.  In addition, 
as growth retardation was not observed in our RAPSN patients the mutations 
identified may have had a less severe effect on early fetal development and fetal 
growth. Siblings reported in a further family were not lethally affected, although they 
had severe respiratory distress. CHRNA1 and CHRND mutations have been found in 
cases of LMPS/FADS associated with pterygia and congenital anomalies such as cleft 
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palate and cardiac defect. However, central nervous system anomalies were not 
present (Michalk et al., 2008).  
 
Based on the current understanding of the underlying molecular pathology, a 
molecular genetic diagnostic pathway was designed for the investigation of 
EVMPS/LMPS/FADS. CHRNG analysis was recommended for all families with 
likely autosomal recessive EVMPS, as the detection rate was estimated to be in the 
order of one quarter. For the LMPS/FADS families the presence of central nervous 
system malformations may suggest an alternative pathology and therefore the 
identification of an acetylcholine receptor pathway gene was considered to be low. 
CHRNG mutation analysis was also recommended for LMPS/FADS patients with 
pterygia, followed by CHRNA1 and CHRND if this was negative. In the absence of 
pterygia, it was suggested that RAPSN and DOK7 mutation analysis should be 
pursued before CHRNG, CHRNA1 and CHRND although the mutation detection rate 
for each individual gene is not expected to be high. 
 
In summary, mutations in AChR pathway component genes are relevant for a wide 
range of FADS spectrum families. The identification of the molecular basis of these 
disorders may be of therapeutic relevance for survivors, for example the attenuation of 
the respiratory symptoms due to AChR pathway gene mutations by the development 
of specific targeted treatments. It is known that RAPSN-associated CMS may respond 
to acetylcholine esterase inhibitors which increase the quantity and duration of 
acetylcholine in the synapse and 3,4-diaminopyridine which the enhances the 
presynaptic release of acetylcholine. Although administration of 3,4-diaminopyridine 
may be limited because of central as well as its peripheral nervous system effects, 
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treatment may be lifesaving for patients presenting with severe disease such as 
respiratory failure at birth and during periods of intercurrent illnesses when clinical 
deterioration may occur, (Schara and Lochmuller, 2008). Empiric treatment of DOK7 
myasthenia with β-adrenergic agonists such as salbutamol is effective and may 
ameliorate the symtoms for survivors identified with severe disease (Engel et al., 
2007). Ephedrine has also been reported to be effective in enhancing neuromuscular 
junction transmission in this patient group however the mechanism of action is 
unclear (Lashley et al., 2010). In addition, persistence of fetal acetylcholine receptor 
subunits in the postnatal neuromuscular junction in CMS may indicate that up-
regulation of other molecules may lead to a partial therapeutic rescue strategy (Ohno 
et al., 1997). However these strategies are unlikely to improve the prognosis for 
severe in utero disease because of the adverse effects on early fetal development of 
very impaired neuromuscular junction transmission, and the presence of bilallelic null 
mutations which may limit the therapeutic response even if an adequate in utero 
dosage can be achieved with minimal maternal side effects.   
 
There is likely to be extensive locus heterogeneity in LMPS/FADS, and as further 
EVMPS/LMPS/FADS genes are identified, utilisation of second generation 
sequencing techniques for diagnostic testing is likely to be a more efficient and cost 
effective genetic testing strategy. Discovery of novel genes causing this phenotype 
was commenced using next generation sequencing technologies. Although not 
successful in identifying a definite pathogenic cause in the family selected for study, 
this provides important insights into some of the challenges that have to be overcome 
in using this technology. It is clear that there are likely to be other AChR genes 
implicated in this group of patients as well as severe mutations in other genes, for 
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example the congenital myopathy genes, critical for development of the fetal motor 
pathway.  
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Future Work 
 
Using our MPS / FADS cohort, further study of the underlying molecular mechanisms 
of this group of conditions is underway. Further analysis of other genes implicated in 
CMS, such as MuSK (Chevessier et al., 2004), may further expand the role of 
defective signal transmission at the neuromuscular junction in the MPS/fetal akinesia 
sequence. A recent single case of Escobar syndrome with nemaline myopathy due to a 
homozygous TPM2 mutation (Monnier et al., 2009) suggests muscle sarcomere genes 
may be implicated in the development of the MPS/FADS phenotype.  
 
The application of next generation sequencing technologies is likely to expedite the 
identification of novel candidate genes. However it will be important to continue to 
collect clinical phenotypic information, to help in clarifying the significance of any 
sequence variants detected, enable the study of genotype phenotype correlations and 
to inform the interpretation of the molecular results. Strategies such autozygosity 
mapping in consanguineous families may continue to provide valuable information 
about the genetic regions to be targeted for efficient mutation detection.  
 
There is considerable overlap in the genetic causes of FADS and arthrogryposis. In 
the West Midlands region we have developed an expertise in the diagnosis and 
management of arthrogryposis-related conditions. We have a regional multi-
disciplinary arthrogryposis service for adult and paediatric patients and access to 
established fetal medicine departments and fetal pathology expertise. In order to 
provide the optimum service for patients and their families it will be important to 
develop effective collaboration between the clinicians, the diagnostic genetics service 
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laboratory and the research scientists. This will facilitate collection of phenotyping 
information, efficient diagnostic investigation pathways and appropriate genetic 
counselling advice, as well as the development of more effective diagnostic testing 
strategies using multi-gene panels, the identification of novel disease genes, genetic 
mechansims and genetic modifiers of disease, and therapeutic targets for future study. 
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